Author: "M., Tarallo" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"M., Tarallo"' showing total 160 results

Start Over Author "M., Tarallo"

160 results on '"M., Tarallo"'

1. Editorial: Endocrine malignancies: from pathophysiology to current clinical and surgical therapeutic approaches

Author: M. Tarallo, L. Petramala, and B. Altieri
Subjects: endocrine tumor, thyroid, parathyroid, adrenal gland, endocrine surgery, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published: 2023
Full Text: View/download PDF

2. Genomic, effector protein and culture-based analysis ofCyclaneusma minusin New Zealand provides evidence for multiple morphotypes

Author: M. Tarallo, K. Dobbie, L. Nunes Leite, T. Waters, K. Gillard, D. Sen, R.L. McDougal, C.H. Mesarich, and R.E. Bradshaw
Abstract: Cyclaneusma needle cast, caused byCyclaneusma minus, affectsPinusspecies around the world. Previous studies suggested the presence of two distinct morphotypes in New Zealand, ‘verum’ and ‘simile’. Traditional mycological analyses revealed a third morphotype with clear differences in colony morphology and cardinal growth rates at varying temperatures. Genome sequencing of eightC. minusisolates provided further evidence of the existence of a third morphotype, named ‘novus’ in this study. To further analyse these morphotypes, we predicted candidate effector proteins for all eight isolates, and also characterized a cell-death eliciting effector family, Ecp32, which is present in other pine phytopathogens. In concordance with their distinct classification into three different morphotypes, the number of Ecp32 family members differed, with patterns of pseudogenization and some family members being found exclusively in some morphotypes. We also showed that proteins belonging to the Ecp32 family trigger cell death responses in non-hostNicotianaspecies, and, as previously demonstrated for other plant pathogens, theC. minusproteins belonging to the Ecp32 family adopt a β-trefoil fold. Understanding the geographical range and variations in virulence and pathogenicity of these morphotypes will provide a better understanding of pine needle diseases as well as enable the development of more durable methods to control this disease.
Published: 2023
Full Text: View/download PDF

3. Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study

Author: Fabio Medas, Chiara Dobrinja, Ebtesam Abdullah Al-Suhaimi, Julia Altmeier, Said Anajar, Akif Enes Arikan, Irina Azaryan, Lovenish Bains, Giancarlo Basili, Hakan Bolukbasi, Marco Bononi, Farzad Borumandi, Mehmet Buğra Bozan, Gabriela Brenta, Laurent Brunaud, Maximilian Brunner, Antoine Buemi, Gian Luigi Canu, Federico Cappellacci, Sara Burchfield Cartwright, Ignasi Castells Fusté, Beatriz Cavalheiro, Giuseppe Cavallaro, Andres Chala, Shun Yan Bryant Chan, John Chaplin, Mustafa Sajjad Cheema, Costanza Chiapponi, Maria Grazia Chiofalo, Emmanuel Chrysos, Annamaria D'Amore, Michael de Cillia, Carmela De Crea, Nicolò de Manzini, Leandro Luongo de Matos, Loredana De Pasquale, Paolo Del Rio, Marco Stefano Demarchi, Muthuswamy Dhiwakar, Gianluca Donatini, Jose Miguel Dora, Valerio D'Orazi, Viyey Kishore Doulatram Gamgaram, Vitalijus Eismontas, El Hassane Kabiri, Hadj Omar El Malki, Islam Elzahaby, Octavian Enciu, Antoine Eskander, Francesco Feroci, David Figueroa-Bohorquez, Dimitrios Filis, Gorostidi François, Pedro Frías-Fernández, Armando Gamboa-Dominguez, Volkan Genc, Davide Giordano, Antonio Gómez-Pedraza, Giuseppa Graceffa, James Griffin, Sofia Cuco Guerreiro, Karan Gupta, Keshav Kumar Gupta, Angela Gurrado, Jiannis Hajiioannou, Tommi Hakala, Wirsma Arif Harahap, Lindsay Hargitai, Dana Hartl, Andrzej Hellmann, Jiri Hlozek, Van Trung Hoang, Maurizio Iacobone, Nadia Innaro, Orestis Ioannidis, J H Isabelle Jang, Jose Candido Xavier-Junior, Milan Jovanovic, Reto Martin Kaderli, Fahmi Kakamad, Krzysztof Kaliszewski, Martin Karamanliev, Hiroshi Katoh, Andro Košec, Bozidar Kovacevic, Luiz Paulo Kowalski, Robert Králik, Sanjay Kumar Yadav, Adriána Kumorová, Savvas Lampridis, Konstantinos Lasithiotakis, Jean-Christophe Leclere, Eugene Kwong Fei Leong, Melvin Khee-Shing Leow, James Y Lim, Leonardo S Lino-Silva, Shirley Yuk Wah Liu, Núria Perucho Llorach, Celestino Pio Lombardi, Javier López-Gómez, Eleonora Lori, Lourdes Quintanilla-Dieck, Roberta Lucchini, Amin Madani, Dimitrios Manatakis, Ivan Markovic, Gabriele Materazzi, Haggi Mazeh, Giuseppe Mercante, Goswin Yason Meyer-Rochow, Olgica Mihaljevic, Julie A Miller, Michele Minuto, Massimo Monacelli, Francesk Mulita, Barbara Mullineris, José Luis Muñoz-de-Nova, Fábio Muradás Girardi, Saki Nader, Tangjaturonrasme Napadon, Constantinos Nastos, Chiara Offi, Ohad Ronen, Luigi Oragano, Aida Orois, Yongqin Pan, Emmanouil Panagiotidis, Ramakanth Bhargav Panchangam, Theodosios Papavramidis, Pradipta Kumar Parida, Anna Paspala, Òscar Vidal Pérez, Sabrina Petrovic, Marco Raffaelli, Constanza Fernanda Ramacciotti, Tomas Ratia Gimenez, Ángel Rivo Vázquez, Jong-Lyel Roh, Leonardo Rossi, Alvaro Sanabria, Alena Santeerapharp, Arseny Semenov, Sanjeewa Seneviratne, Altinay Serdar, Patrick Sheahan, Sean C Sheppard, Rachel L Slotcavage, Constantin Smaxwil, Soo Young Kim, Salvatore Sorrenti, Eleftherios Spartalis, Chutintorn Sriphrapradang, Mario Testini, Yigit Turk, George Tzikos, Kristina Vabalayte, Kelly Vargas-Osorio, Rafael Sebastián Vázquez Rentería, David Velázquez-Fernández, Sanura Malinda Pallegoda Vithana, Levent Yücel, Erwin Danil Yulian, Petra Zahradnikova, Paul Zarogoulidis, Evgeniia Ziablitskaia, Anna Zolotoukho, Pietro Giorgio Calò, A Abdallah, AL Abentroth, V Acheimastos, M Agunaoun, HM Al Bisher, A Al Ghuzlan, H Alakus, M Alkan, MC Almaraz Almaraz, K Amram, S Anesidis, E Anestiadou, D Angelucci, GL Ansaldo, MI Antonopoulou, M Arciniegas, C Armellin, G Arredondo Saldaña, J Astl, E Athanasakis, S Avenia, H Aydın, B Baba, J Babala, MV Banús, LA Barba-Valadez, SV Barcons, F Battafarano, A Bayat, RMC Bella, F Benariba, S Bernardi, EG Bignami, M Bitenc, S Bitsianis, JDD Bolaños de la Torre, E Bonati, T Bonetti, FA Borges, K Bouchagier, M Boudina, A Bourial, I Breuskin, P Brock, C Bruns, MC Burlacu, T Burton, M Buta, D Buzanakov, C Caliseo, D Callanan, V Calu, JM Cameselle-Teijeiro, DJ Camilo-Junior, S Canberk, V Candalise, F Candanedo-Gonzalez, LJ Carrillo Lizarazo, GB Carvalho, D Casallas, C Casolino, L Castellani, C Castillo Morales, G Chambon, V Chatzipavlidou, R Chernikov, A Chorti, TCM Chow, A Chrisoulidou, E Chrysos, S Conrado-Neto, D Cordova García, A Corigliano, A Crocco, A Cuesta, M Čukman, LS Curto, RA Damilano, R D'Anna, M De, A De Virgilio, D Dellaportas, L Demarquet, A Devresse, G Di Meo, R Diaz Pedrero, D Dimitrov, Z Dmitry, P Domínguez Garijo, O Dulgeroglu, AC Dural, A Eksi, M El Hammoumi, H El Kaoui, G Eleni, A Elliyanti, Ş Ersöz, M Escobar-Jiménez, L Fedorova, L Feeley, E Fernández Rodríguez, F Ferreli, A Filoia, A Fingeret, A Francescato, F Gaino, F Galiandro, JF Gallegos-Hernández, G Garas, F García Lorenzo, JP García-Chávez, M Gaudiello, S Gay, S Gerasimos, M Gerek, R Gervasi, A Giordano, B Gjeloshi, L Gocký, E Golubinskaya, S González Romero, C González-Mínguez, M Goran, A Gosman, M Granados Garcia, E Greco, M Grünbart, R Grützmann, J Guerlain, XG Guirao, D Guzey, A Hajjij, O Hamdy, MS Hameed, LA Hauth, JD Hernández-Acevedo, JF Hernandez-Carrillo, F Hevilla Sánchez, H Hoi, K Hongkwon, R Hu Zhu, E Huang, K Hyeung Kyoo, V Ignjatovic, A Ioannidis, A Iossa, A Işık, D James, L Jung Hoon, H Kara, J Karajovic, D Kartini, D Khambri, I Kholová, M Kisiel, M Knežević, YQ Koh, C Konca, C Kosmidis, G Kotsovolis, LP Kowalski, R Kralik, P Kuczma, BG Kuravi, A Kurnia, V Kyriaki, CM Lai, B Lallemant, AA Lardhi, S Leboulleux, JW Lee, G Lelli, M Leutner, MY Lim, CM Lim, A Llanos, X Lo, T Loderer, MA López-Corrales, M Ludwig, FF Magnabosco, C Maheo, AL Maia, O Makay, P Maksimova, S Mallick, C Mallouk, Z Mamani, S Mandal, M Manyalich Blasi, G Marincola, M Marulanda, M Mavromati, S Mayilvaganan, S Metso, A Micalizzi, A Michalopoulos, K Min-Su, A Miron, AK Mishra, C Misso, C Mittermair, Y Morosán Allo, M Mourad, M Moysidis, F Nabhan, R Nasiri, C Nastos, KY Ngiam, C Nomine-Criqui, AM Ntziovara, JM Nuño Vázquez-Garza, V Nutautiene, K Obtulovičová, L O'Keeffe, NO Okudur, P Ossola, E Ovejero Merino, M Ozdemir, A Pangonis, SS Panigoro, A Panuzi, D Papaconstantinou, N Pardo Matamoros, S Paschou, A Pasculli, K Paterakis, K Peiris, F Pennestrì, M Peppa, P Perdikaris, I Perdikaris, RH Pérez-Soto, S Piana, M Piccoli, D Pietrasanta, G Placentino, I Pliakos, A Polistena, A Pongtippan, G Potard, V Quinn, P Rahul, T Ramos, A Rankin, P Ratnayake, J Reuto-Castillo, A Ridolfo, J Rios-Valencia, P Riss, E Rival, J Rivillas, D Roi, EM Rollo, A Romanchishen, M Romito, J Rotnagl, B Rovcanin, G Russo, M Sabol, S Saki, S Saleh, A Salih, A Saltiki, G Salvador-Camarmo, DK Samal, S Sánchez-Flores, K Sapalidis, D Sarin, H Sarin, N Savkovic, RS Scheffel, AL Scheinpflug, C Scheuba, N Scheyer, M Schmidt, O Senashova, E Serafini, ML Serrano Arévalo, J Shank, ML Shindo, M Shoshkova, M Shvan, M Sičák, TG Silva, O Simó Guerrero, V Skuletic, N Slijepcevic, Z Slovic, P Soares, A Somova, S Soto, S Spiezia, V Stankovic, KJ Stephenson, E Straub, M Summa, S Surani, AA Syed, S Symeonidis, A Taciak, M Tarallo, A Tarle, N Tasis, K Tausanovic, L Tchabashvili, M Thierry, U Tokarczyk, EA Toma, S Topuz, F Torresan, C Uras, C Vaccaro, Á Valdés de Anca, M Valentini, E Varaldo, JG Vartanian, GI Verras, A Vithanage, H Wijayalathge, P Wiriyaamornchai, YLC Wong, P Wongwattana, S Xenaki, S Xie, M Xu, W Yang, S Yilmaz, YF Yılmaz, T Yotsov, MT Zahid, A Zielke, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service de chirurgie et transplantation abdominale, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, and UCL - (SLuc) Service de néphrologie
Subjects: Endocrinology, Endocrinology, Diabetes and Metabolism, Internal Medicine
Abstract: Since its outbreak in early 2020, the COVID-19 pandemic has diverted resources from non-urgent and elective procedures, leading to diagnosis and treatment delays, with an increased number of neoplasms at advanced stages worldwide. The aims of this study were to quantify the reduction in surgical activity for indeterminate thyroid nodules during the COVID-19 pandemic; and to evaluate whether delays in surgery led to an increased occurrence of aggressive tumours. In this retrospective, international, cross-sectional study, centres were invited to participate in June 22, 2022; each centre joining the study was asked to provide data from medical records on all surgical thyroidectomies consecutively performed from Jan 1, 2019, to Dec 31, 2021. Patients with indeterminate thyroid nodules were divided into three groups according to when they underwent surgery: from Jan 1, 2019, to Feb 29, 2020 (global prepandemic phase), from March 1, 2020, to May 31, 2021 (pandemic escalation phase), and from June 1 to Dec 31, 2021 (pandemic decrease phase). The main outcomes were, for each phase, the number of surgeries for indeterminate thyroid nodules, and in patients with a postoperative diagnosis of thyroid cancers, the occurrence of tumours larger than 10 mm, extrathyroidal extension, lymph node metastases, vascular invasion, distant metastases, and tumours at high risk of structural disease recurrence. Univariate analysis was used to compare the probability of aggressive thyroid features between the first and third study phases. The study was registered on ClinicalTrials.gov, NCT05178186. Data from 157 centres (n=49 countries) on 87 467 patients who underwent surgery for benign and malignant thyroid disease were collected, of whom 22 974 patients (18 052 [78·6%] female patients and 4922 [21·4%] male patients) received surgery for indeterminate thyroid nodules. We observed a significant reduction in surgery for indeterminate thyroid nodules during the pandemic escalation phase (median monthly surgeries per centre, 1·4 [IQR 0·6-3·4]) compared with the prepandemic phase (2·0 [0·9-3·7]; p
Published: 2023

4. T.02.5 OXIDATIVE STRESS IN DIVERTICULAR DISEASE: MITOCHONDRIA INVOLVEMENT OF IN THE DIFFERENT CLINICAL PHENOTYPES

Author: M. Cappelletti, R. Vona, A. Pisano, A. Gioia, L. Castagneto Gissey, M. Tarallo, P. Matarrese, C. Giordano, C. Severi, and L. Pallotta
Subjects: mitochondria, Hepatology, diverticular disease, Gastroenterology, oxidative stress
Published: 2023

5. Exigência a boro em cultivares de soja

Author: A. M. C. Furlani, R. T. Tanaka, M. Tarallo, M. F. Verdial, and H. A. A. Mascarenhas
Subjects: Glycine max (L.) Merrill, micronutriente, solução nutritiva, seleção de cultivares, Agriculture (General), S1-972
Abstract: O conhecimento quanto à exigência a boro de genótipos da soja pode ser relevante para: recomendações de corretivos e fertilizantes, recomendação de cultivares e programas de melhoramento. O objetivo deste trabalho foi estudar a resposta de cultivares de soja à adição de doses de boro em solução nutritiva. O experimento foi realizado em casa de vegetação do Instituto Agronômico de Campinas - IAC, Campinas (SP). Foram estudados quatro cultivares de soja (IAC-1, IAC-8, IAC-15 e IAC-17) e cinco doses de boro (0,0; 0,05; 0,20; 0,80 e 2,00 mg L-1 de B), utilizando-se delineamento em blocos ao acaso, em esquema fatorial com cinco repetições. As plantas foram avaliadas quanto aos sintomas de deficiência à toxidez, produção de matéria seca, altura das plantas, teores críticos de B nas folhas, B absorvido pela planta e teores de P, K, Ca e Mg. As plantas foram colhidas no início do florescimento para determinação da massa da matéria seca e teores de nutrientes. Os teores limites de B nas folhas para a deficiência variaram de 25 a 30 mg kg-1, mostrando diferenças entre os cultivares nesta susceptibilidade. O sintoma inicial de toxidez foi observado a partir da dose de 0,8 mg L-1 de B na solução, cujo teor correspondente nas folhas foi de 83 mg kg-1 de B (média dos cultivares), enquanto o acúmulo máximo de matéria seca total ocorreu para concentrações na solução estimadas entre 0,1 e 0,2 mg L-1. A severidade dos sintomas visuais variou entre cultivares dentro do mesmo tratamento, indicando diferentes tolerâncias ao excesso do nutriente. Assim, quanto aos sintomas de deficiência e de toxidez, o cv. IAC-1 foi o mais susceptível à deficiência e à toxidez de B, e o cv. IAC-17 foi, aparentemente, o mais tolerante ao excesso de B. Os cvs. IAC-8 e o IAC-15 acumularam as maiores quantidades de B, mesmo nos tratamentos com baixa concentração de B na solução. Os teores de P, K, Ca e Mg nas folhas não variaram significativamente entre os tratamentos que receberam boro (0,05 a 2,0 mg L-1), com exceção das plantas com deficiência severa.
Published: 2001
Full Text: View/download PDF

6. Venous thromboembolism prophylaxis in plastic surgery: state of the art and our approach

Author: U, Redi, G, Marruzzo, L, Codolini, A, Chistolini, M, Tarallo, M, Marcasciano, F, Lo Torto, F R, Grippaudo, D, Casella, and D, Ribuffo
Subjects: Postoperative Complications, Risk Factors, Humans, Venous Thromboembolism, Surgery, Plastic, Risk Assessment, Algorithms, VTE, thromboembolism, plastic surgery, prophylaxis, guideline, venous thromboembolism, chemoprevention, risk assessment
Abstract: The issue of prevention of thromboembolism in plastic surgery is a rather controversial subject. The actual frequency of VTE among plastic surgery patients is probably higher than we know. Although several studies have shown that chemoprophylaxis likely increases rates of re-operative hematoma by less than one percent, surgeons are strongly resistant to adopting chemoprophylaxis due to the fear of increased bleeding and its complications.A literature review was conducted. The 2012 ACCP guidelines suggest the use of the 2005 Caprini score as the most widely used and well-validated individualized risk-stratification tool. We propose a modified 2005 Caprini score, with specific changes pertaining to plastic surgery, in which we combine a patient risk stratification model and a procedure-driven approach explicitly indicating what procedures have to be considered at high or low risk.The risk of venous thromboembolism in plastic surgery cannot be disregarded. However, the plastic surgery literature still lacks high-level evidence for appropriate means of VTE prophylaxis, although an increasing amount of attention has been paid to the topic. We suggest the development of an international guideline, based on plastic surgical data, using a validated risk assessment model, which combines the surgical risk with the patient-related risk.Determining the proper venous thromboembolism prophylaxis is a clinical decision that should be made on a patient-to-patient basis. The algorithm presented in this article is meant to simplify this complex problem and to help expedite and clarify the decision-making process.
Published: 2021

7. The association between disease activity and patient-reported outcomes in patients with moderate-to-severe ulcerative colitis in the United States and Europe

Author: Daniel Bluff, Danielle Bargo, M. Tarallo, Joseph C. Cappelleri, Leonardo Salese, James Lucas, Marco DiBonaventura, Alessandro Armuzzi, and Benjamin Hoskin
Subjects: Quality of life, Adult, Male, medicine.medical_specialty, Work impairment, Severity of Illness Index, Inflammatory bowel disease, Activity impairment, Disease activity, 03 medical and health sciences, 0302 clinical medicine, Germany, Surveys and Questionnaires, Internal medicine, medicine, Humans, media_common.cataloged_instance, Patient Reported Outcome Measures, lcsh:RC799-869, European union, Colitis, Retrospective Studies, media_common, Patient-reported outcomes, business.industry, Confounding, Gastroenterology, General Medicine, Hepatology, medicine.disease, Ulcerative colitis, United Kingdom, United States, Italy, Spain, 030220 oncology & carcinogenesis, lcsh:Diseases of the digestive system. Gastroenterology, Colitis, Ulcerative, Female, 030211 gastroenterology & hepatology, France, business, Research Article
Abstract: Background Patients with ulcerative colitis (UC) experience periods of recurring and episodic clinical signs and symptoms. This study sought to establish the association between disease activity and health-related quality of life (HRQoL) and other patient-reported outcomes. Methods United States (US) and European Union 5 ([EU5]; i.e., France, Germany, Italy, Spain, and the United Kingdom) data from the 2015 and 2017 Adelphi Inflammatory Bowel Disease-Specific Programme (IBD-DSP) were used. The IBD-DSP is a database of retrospective patient chart information integrated with patient survey data (EuroQoL-5 Dimensions [EQ-5D], Short Quality of Life in Inflammatory Bowel Disease Questionnaire [SIBDQ], and Work Productivity and Activity Impairment-Ulcerative Colitis [WPAI-UC] questionnaire). Using available chart information, physicians classified their moderate-to-severe patients into one of the following categories: remission with a Mayo endoscopic score = 0 (“deep remission”), remission without a Mayo endoscopic score = 0 (“remission”), or active disease. Differences among disease activity categories with respect to patient-reported outcomes were analyzed using generalized linear models, controlling for confounding variables. Results N = 289 and N = 1037 patient charts with linked surveys were included from the US and EU5, respectively. The disease activity distribution was as follows: active disease = 40.1% (US) and 33.6% (EU5); remission = 48.0 and 53.0%; deep remission = 11.9 and 13.3%. Patients with active disease reported significantly lower levels of EQ-5D health state utilities (adjusted mean [AdjM] = 0.87 [US] and 0.78 [EU5]) compared with remission (AdjM = 0.92 and 0.91) and deep remission (AdjM = 0.93 and 0.91) (all P Conclusions Among patients with moderate-to-severe UC in the US and EU5, active disease was associated with significant impairments in HRQoL, work and leisure activities. These results reinforce the importance, to both the patient and society, of achieving some level of remission to restore generic and disease-related HRQoL and one’s ability to work productively.
Published: 2020
Full Text: View/download PDF

8. Relationship between disease activity status or clinical response and patient-reported outcomes in patients with non-radiographic axial spondyloarthritis

Author: Ron Pedersen, Maxime Dougados, Désirée van der Heijde, Lisa Marshall, Wen-Chan Tsai, M. Tarallo, Bonnie Vlahos, Diego Luis Saaibi, and Heather Jones
Subjects: Adult, Male, medicine.medical_specialty, Visual analogue scale, lcsh:Computer applications to medicine. Medical informatics, Etanercept, External validity, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Internal medicine, medicine, Back pain, Humans, Spondylitis, Ankylosing, 030212 general & internal medicine, Patient Reported Outcome Measures, Axial spondyloarthritis, Non-radiographic axial spondyloarthritis, BASDAI, 030203 arthritis & rheumatology, Ankylosing spondylitis, business.industry, Research, Public Health, Environmental and Occupational Health, General Medicine, Middle Aged, medicine.disease, Confidence interval, Treatment Outcome, Antirheumatic Agents, Patient-reported outcome measures, Disease Progression, Quality of Life, lcsh:R858-859.7, Female, medicine.symptom, business, medicine.drug
Abstract: Background We assessed the external validity of composite indices Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Assessment in SpondyloArthritis international Society (ASAS) 40 response (ASAS40) by evaluating the correlations between the changes in some patient reported outcomes (PROs) for patients with non-radiographic axial spondyloarthritis (nr-axSpA) and the changes in the scores of the composite indices. Methods This was a post-hoc analysis of data from the EMBARK study in patients with nr-axSpA treated with etanercept. PROs were grouped according to ASDAS status (inactive [ 3.5]), patient achievement of > 50% improvement in BASDAI (BASDAI50 responders), and > 40% improvement in ASAS (ASAS40 responders) at 104 weeks. Analyses were conducted on observed cases available at Week 104. Changes in PROs from Baseline to Week 104 were assessed using analysis of covariance with adjustment for baseline with linear contrast. Results Higher ASDAS disease activity at 104 weeks was associated with lower long-term improvement from baseline in PROs (e.g., total back pain [visual analog scale, cm (95% confidence interval): − 4.58 (− 4.95, − 4.21), − 3.86 (− 4.28, − 3.43), − 2.15 (− 2.68, − 1.61), and 1.30 (− 0.51, 3.12) for inactive, low, high, and very high ASDAS disease activity, respectively; Multidimensional Fatigue Inventory (MFI) general fatigue: − 4.77 (− 5.70, − 3.84), − 2.96 (− 4.04, − 1.87), − 1.00 (− 2.32, 0.31), and 2.14 (− 2.10, 6.38); all p p p Conclusion Composite indices are valid for monitoring treatment response and adequately reflect treatment-related changes experienced by patients with nr-axSpA. Trial registration ClinicalTrials.gov identifier: NCT01258738. Registered 9 December 2010.
Published: 2020

9. Criticism of learning curve in laparoscopic adrenalectomy. A systematic review

Author: M, Tarallo, D, Crocetti, E, Fiori, P, Sapienza, C, Letizia, G, De Toma, and G, Cavallaro
Subjects: Adrenal tumor, Laparoscopic adrenalectomy, Lateral transperitoneal laparoscopic adrenalectomy, Learning curve, Adrenal Gland Neoplasms, Adrenalectomy, Humans, Intraoperative Complications, Laparoscopy, Length of Stay, Operative Time, Learning Curve
Abstract: Laparoscopic adrenalectomy (LA) has become the treatment of choice for benign adrenal lesions. Lateral Transperitoneal Laparoscopic Adrenalectomy (LTLA) is considered the gold standard. The number of LTLAs a surgeon must perform, in order to complete his learning curve, is not well defined in Literature. Moreover, the few papers dealing with the learning curve for LTLAs show controversial results and consider different evaluation parameters.The systematic review has been carried out according to PRISMA statement. The literature search included PubMed and Scopus database. Hand searching of reference lists of previous review articles and relevant studies was also performed. The search string was "learning curve AND laparoscopic adrenalectomy".A total of 9 papers met the inclusion criteria out of 94 non duplicate citations. The aim of this systematic review is to provide a multidimensional evaluation by bringing into focus evaluation parameters of surgical performance, (operative time, intraoperative complications, conversion rate and blood loss), factors related to patient's pathology (side, size, adrenal pathology) and surgeon-specific properties.Operative time, intraoperative bleeding, intraoperative complications and conversion rate are the main parameters that have been considered for the achievement of learning curve, and for each there are discrepancies, mainly due to the relative rarity of adrenal tumors, and so for difficulties in obtaining approper analysis that could establish an effective learning curve. So, further evaluations in larger experience are needed.
Published: 2020

10. P11 Etanercept persistence in juvenile idiopathic arthritis up to adult care in patients in Germany: a real-world analysis

Author: Kirsten Minden, Nicholas Hudson, Christen M Gray, Gerd Horneff, Cinzia Curiale, Andreas Blum, M. Tarallo, Ana Cristina Hernandez Daly, and Joseph C. Cappelleri
Subjects: Persistence (psychology), Pediatrics, medicine.medical_specialty, business.industry, Arthritis, Adult care, medicine.disease, Etanercept, Rheumatology, Rheumatoid arthritis, medicine, Juvenile, Pharmacology (medical), In patient, Young adult, business, medicine.drug
Abstract: Background Although juvenile idiopathic arthritis (JIA) occurs early in life, patients can require long-term treatment into adulthood due to active disease or flares. However, most available studies show that there are gaps in care during and after the transition to adult care. Transition has been associated with higher dropout rates, and there is limited evidence on treatment persistence in JIA patients. The current analysis evaluates etanercept bio-original (ETNBo) persistence up to 5 years and reports diagnostic patterns in early adolescence and young adults in Germany. Methods Patients with JIA (ICD10: M08) between 2-30 years of age with a first recorded ETNBo prescription between 1-January-2008 and 31-December-2012 were retrospectively identified in German health insurance claims data. Patients were followed until 31-December-2015 or end-of-record, whichever came first. Index date was set at the first ETNBo prescription after a 12-month etanercept-free look-back period. Patient characteristics, concomitant treatments and prior use of other biologic Disease-modifying antirheumatic Drugs (bDMARD) were evaluated in the 12-month look-back period. The 5-year etanercept treatment persistence, defined as median (95% confidence interval [CI]) months between the index date and a discontinuation (≥90-day treatment gap after last etanercept prescription), was estimated using Kaplan-Meier analysis, overall and for bio-naïve patients. Etanercept WHO defined daily dose (DDD) was adjusted by age; for patients 2-6, 7-10, 11-14 and >15 daily doses were defined as 1.4mg, 3.6mg, 5.4mg and 7.0mg, respectively. The proportion of patients receiving an adult rheumatic diagnosis after the age of 11 was described. Results We identified 125 patients diagnosed with JIA (median age: 15 years; 30% male). At index quarter 56% of patients were in the 11-20 age group. Most patients (94%) were bio-naïve and 46%, 34%, and 17% had concomitant use of NSAIDS, other DMARDS, and corticosteroids, respectively. Overall median persistence was 13 months (95%CI: 10-16; IQR: 5-27). Persistence for the bio-naïve patients was 50% (95%CI: 41-57), 27% (95%CI: 20-34), 16% (95%CI: 10-23), 10% (95%CI: 5-17) and 9% (95%CI: 4-15) at 12, 24, 36, 48, and 60 months respectively. The majority of patients (68%) received an additional diagnosis of rheumatoid arthritis after age 11, while 15% were given other adult rheumatic diagnoses. Only 9% of JIA patients had received no additional diagnosis to JIA. Conclusion This analysis provides important understanding of care in young JIA patients. We observed a decreasing persistence of etanercept therapy as patients progressed in time through the transition period into early adulthood. Importantly, we found that the majority of JIA patients received additional adult diagnoses, which suggests the transition could impact on the clinical management of this disease. Diagnostic patterns, clinical and patient circumstances during this critical period and their impact on persistence requires further analysis. Conflicts of Interest The authors declare no conflicts of interest.
Published: 2019
Full Text: View/download PDF

11. OC.08.1 MYOGENIC OXIDATIVE STRESS IMPAIRES COLONIC LONGITUDINAL MUSCLE IN DIVERTICULAR DISEASE

Author: Lucia Pallotta, E. Fiori, G. Tellan, Marilia Carabotti, Carola Severi, L. Gambardella, M. Tarallo, Barbara Ascione, and A. Cicenia
Subjects: medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, medicine, Diverticular disease, Longitudinal muscle, business, medicine.disease_cause, Oxidative stress
Published: 2020
Full Text: View/download PDF

12. PCN340 TREATMENT OUTCOMES IN LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF HEAD AND NECK PATIENTS WHO SUBSEQUENTLY PROGRESSED: REAL-WORLD EVIDENCE FROM EUROPE AND THE US

Author: M. Tarallo, A. Bailey, Joseph C. Cappelleri, Vaishali Pawar, J. Hall, Grace Foley, and H. Bailey
Subjects: medicine.medical_specialty, business.industry, Health Policy, Treatment outcome, Public Health, Environmental and Occupational Health, Locally advanced, Medicine, Basal cell, Radiology, business, Head and neck, Real world evidence
Published: 2020
Full Text: View/download PDF

13. PCN351 REAL WORLD EVIDENCE ON PATIENT CHARACTERISTICS AND FRONTLINE TREATMENT PATTERNS IN LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK FROM EUROPE AND US

Author: Grace Foley, Joseph C. Cappelleri, H. Bailey, Vaishali Pawar, J. Hall, M. Tarallo, and A. Bailey
Subjects: medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Locally advanced, Medicine, Patient characteristics, Basal cell, Radiology, business, Real world evidence, Head and neck
Published: 2020
Full Text: View/download PDF

14. Depression risk among patients with chronic wounds

Author: P, Fino, G, Di Taranto, A, Pierro, J, Kacjulite, L, Codolini, M G, Onesti, M, Toscani, and M, Tarallo
Subjects: Adult, Aged, 80 and over, Male, Psychiatric Status Rating Scales, Leg Ulcer, chronic wound, depression, wound healing, Middle Aged, Combined Modality Therapy, Chronic Disease, Prevalence, Humans, Wounds and Injuries, Female, Aged
Abstract: A wound is defined as chronic when it requires more than 6 weeks to heal. The link between chronic wounds and depression was first pointed out by House and Hughes in 1996 and later evaluated by other numerous studies. Several studies demonstrate that among chronic skin wounds causing chronical physical disease, the leg ulcers are the most frequently associated with depression. The aim of our study is to evaluate the prevalence of depression in patients with different types of chronic wounds.We enrolled a total of 33 patients with chronic wounds and 33 healthy controls matched by sex and age. Both patients and controls underwent a BDI II survey. We evaluated 33 patients, with a mean age of 71 years (range 25-87), and 33 controls, with a mean age of 73 years (range 31-88).The average score at the BDI II questionnaire was 14.5 and 8, respectively.The depression among patients with chronic wounds has a multifactorial origin that should be treated with a multidisciplinary approach. Since the improvement of the psycho-emotional state means better compliance of the patient, we can also expect a better result in terms of efficacy in chronic wound treatment.
Published: 2019

15. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK

Author: M. Tarallo, Kateryna Onishchenko, and Stamatia T Alexopoulos
Subjects: musculoskeletal diseases, medicine.medical_specialty, Etanercept, Arthritis, Rheumatoid, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, In patient, skin and connective tissue diseases, Intensive care medicine, Biosimilar Pharmaceuticals, business.industry, 030503 health policy & services, Health Policy, Cost impact, Biosimilar, medicine.disease, United Kingdom, 030220 oncology & carcinogenesis, Rheumatoid arthritis, Antirheumatic Agents, Health Resources, Health Expenditures, 0305 other medical science, business, Models, Econometric, medicine.drug
Abstract: Aims: To estimate the cost impact of non-medical switching from originator to biosimilar etanercept in stable patients with rheumatoid arthritis (RA) in the UK. Materials and methods: A cohort-based decision tree model was developed with a 1-year time horizon. The model population included patients with stable RA (patients who responded to originator etanercept treatment with no treatment changes in the previous 6 months). Patients could undergo a non-medical switch to a biosimilar and then switch treatment again, if medically required, after 3–6 months. Data on the proportion of patients switching therapies, baseline healthcare resource use, and impact of switching on resource use were sourced from a survey of 150 rheumatologists from EU5 markets (France, Germany, Italy, Spain, UK). The average impact of switching was evaluated as mean values for change in resource utilization due to switching. Also, low- and high-impact scenarios (lower and upper values of the 95% confidence intervals for change in resource utilization due to switching) were modelled as sensitivity analyses. Cost data came from published UK sources. Results: The model assumed that 5,000 patients were treated with originator etanercept, with 1,259 (25.2%) switching to a biosimilar. Of those, 875 (69.5%) and 384 (30.5%) switched to SB4 and GP2015, respectively. After 3 months, 26.3% of patients who switched treatments did so again: 8.3% back to originator, 3.8% to the other biosimilar, and 14.2% to another biologic. Although originator etanercept was more expensive than the biosimilars, switching was more costly than continuous originator treatment across all impact scenarios. Switching treatment chains had higher overall annual per-patient costs than continuous originator treatment. Switching was associated with increased healthcare resource use. Limitations: Results from this analysis are not transferable to other (non-RA) etanercept indications. Conclusion: Non-medical switching can result in increased payer costs because of increased healthcare resource use following switching.
Published: 2019
Full Text: View/download PDF

16. Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice

Author: Juan J Gomez Reino, Emma Sullivan, Robert Wood, Jose Alvir, Roberto Caporali, Peter C. Taylor, M. Tarallo, James Piercy, Radu Vasilescu, Dean Spurden, Philippe Bertin, and Rieke Alten
Subjects: Disease specific, rheumatoid arthritis, 030213 general clinical medicine, medicine.medical_specialty, treat-to-target, Medicine (miscellaneous), Disease, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, 0502 economics and business, disease-modifying antirheumatic drugs, Medicine, In patient, Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Original Research, lcsh:R5-920, business.industry, Health Policy, 05 social sciences, Treat to target, medicine.disease, Rheumatology, Patient Preference and Adherence, Rheumatoid arthritis, 050211 marketing, Physician satisfaction, business, Antirheumatic drugs, lcsh:Medicine (General), Social Sciences (miscellaneous)
Abstract: Peter C Taylor,1 Rieke Alten,2 Juan J Gomez Reino,3 Roberto Caporali,4 Philippe Bertin,5 Emma Sullivan,6 Robert Wood,6 James Piercy,6 Radu Vasilescu,7 Dean Spurden,8 Jose Alvir,9 Miriam Tarallo10 1Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; 2Department of Internal Medicine II, Rheumatology, Clinical Immunology, and Osteology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany; 3Experimental and Observational Rheumatology and Rheumatology Unit, Fundacion Ramon Dominguez and Rheumatology, Hospital Clinico Universitario, Santiago de Compostela, Spain; 4Division of Rheumatology, IRCCS Foundation Policlinico S. Matteo, University of Pavia, Pavia, Italy; 5Service de Rhumatologie, CHU Dupuytren, Limoges, France; 6Real-World Evidence and Epidemiology, Adelphi Real World, Bollington, UK; 7Medical Affairs, International Developed Markets, Pfizer, Brussels, Belgium; 8Health Economics and Outcomes Research, Pfizer Ltd, Tadworth, UK; 9Statistical Research and Data Science Center, Global Product Development, Pfizer Inc, New York, NY, USA; 10Patient and Health Impact, Pfizer Italia Srl, Rome, Italy Objective: The aim of this study was to identify factors that influence treatment adjustments and adoption of a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) in European practices.Methods: Cross-sectional data were drawn from the Adelphi 2014 RA Disease Specific Programme. Treatment patterns and clinical characteristics were investigated in patients treated with biologic disease-modifying antirheumatic drugs (bDMARDs) vs non-bDMARDs. For the T2T analysis, patients were subdivided into two subsets (RA diagnosis
Published: 2018

17. Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment

Author: Radu Vasilescu, Philippe Bertin, Juan J. Gomez-Reino, Robert Wood, M. Tarallo, Dean Spurden, Emma Sullivan, Rieke Alten, Jose Alvir, James Piercy, Peter C. Taylor, and Roberto Caporali
Subjects: 030203 arthritis & rheumatology, Work productivity, medicine.medical_specialty, business.industry, Patient demographics, Immunology, dmards (biologic), Mean age, Rheumatoid Arthritis, medicine.disease, patient perspective, Disease control, Disease activity, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Internal medicine, Rheumatoid arthritis, medicine, Immunology and Allergy, In patient, 030212 general & internal medicine, Health questionnaire, business
Abstract: Background: Despite the wide array of treatments available for rheumatoid arthritis (RA), some patients continue to report unmet clinical needs. We investigated the extent of inadequate disease control in patients with RA. Methods: Data were drawn from the Adelphi 2014 RA Disease Specific Program in France, Germany, Italy, Spain and the UK. Rheumatologists provided patient demographics, comorbidities, satisfaction with RA control and other clinical details. Patients reported their level of satisfaction and completed the EuroQoL 5-Dimensions health questionnaire and Work Productivity and Activity Impairment questionnaire. Patients had been on their current therapy ≥3 months and had 28-joint disease activity scores (DAS28) reported. Adequately controlled (DAS28 ≤3.2) and inadequately controlled (DAS28 >3.2) patient cohorts were compared using univariate tests. Results: Of 1147 patients, 74% were female, the mean age was 52 years and the mean time since RA diagnosis was 7 years. Twenty-seven percent of patients had inadequately controlled RA whereas 73% had adequately controlled RA. Inadequately controlled patients were more affected clinically versus adequately controlled patients; 69% versus 13% had moderate/severe RA, the current level of pain was 4.6 versus 2.3, and 67% versus 41% experienced flares, respectively (all p Conclusion: RA was insufficiently controlled in over a quarter of patients despite their current therapy and this had a negative impact on the patients.
Published: 2018

18. PBI10 REAL WORLD SWITCHING PATTERNS OF ETANERCEPT ORIGINAL AND BIOSIMILAR IN GERMANY

Author: C. Miglio, R. Alten, C. Gray, and M. Tarallo
Subjects: Actuarial science, Health Policy, Economics, Econometrics and Finance (miscellaneous), medicine, Biosimilar, Business, Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Etanercept, medicine.drug
Published: 2019
Full Text: View/download PDF

19. Oncoplastic conservative surgery for breast cancer: long-term outcomes of our first ten years experience

Author: C, Calabrese, D, Casella, G, Di Taranto, M, Marcasciano, A, Kothari, S, Sordi, L, Barellini, F, Lo Torto, M, Tarallo, A, Perra, A, Fausto, and D, Ribuffo
Subjects: Adult, Aged, 80 and over, Time Factors, Databases, Factual, oncoplastic, conservative surgery, breast cancer: long-term outcomes, Patient Selection, Clinical Decision-Making, Margins of Excision, Breast Neoplasms, Middle Aged, Mastectomy, Segmental, Tumor Burden, Treatment Outcome, Risk Factors, Disease Progression, Humans, Female, Prospective Studies, Neoplasm Metastasis, Neoplasm Recurrence, Local, Aged
Abstract: The main goal of oncoplastic breast surgery (OBS) is to optimize cosmetic outcomes and reduce patient morbidity, while still providing an oncologically-safe surgical outcome and extending the target population of conservative surgery. Although the growing number of reported experiences with oncoplastic surgery, few studies account for the long-term outcomes.Between January 2000 and December 2010, 1024 consecutive oncoplastic surgeries were performed and prospectively included in a database. Demographic data, histological and oncological evaluation and surgical complications were recorded. The role of tumor and patients' characteristics on the development of local recurrence and metastases were assessed by multivariate analysis.Median follow up was 74.2 months. The average age of patients was 56.24. In 869 patients (84.9%) an invasive tumor and in 155 (15.1%) an in situ tumor (11% DCIS and 4% LIN) was found. The average size of the tumor was 24.5 mm. A positive margin presented in 67 (6.5%) patients. Forty patients (50%) underwent re-excision and 39 (49.4%) underwent mastectomy. The overall breast conservation rate was 96.2%. Reported complications were: 17 wound infections (1.7%); 106 hematomas (10.4%); 94 lymphorrheas (9.2%), 48 partial wound dehiscence (4.7%). Local recurrences (LR) were observed in 49 patients (4.7%). The risk of local recurrence was significantly higher in the group of patients with lymphovascular invasion and with high grade (G) (p0.05). 52 (5.07%) distant metastases were reported and the related risk was significantly higher in the group of patients with lymphovascular invasion and with negative receptors (p0.05).Oncoplastic surgery provides an acceptable oncological long-term outcome and can be used to treat with conservative surgery also a selected population of patients who would had otherwise undergone mastectomy in the past.
Published: 2018

20. P255 Perceived disease severity and treatment satisfaction among patients with ulcerative colitis in Europe

Author: Daniel Bluff, Benjamin Hoskin, M. Tarallo, Alessandro Armuzzi, Leonardo Salese, James Lucas, Marco DiBonaventura, Danielle Bargo, Joseph C. Cappelleri, and Cem Kayhan
Subjects: Treatment satisfaction, medicine.medical_specialty, Disease severity, business.industry, Internal medicine, Gastroenterology, medicine, General Medicine, medicine.disease, business, Ulcerative colitis
Published: 2019
Full Text: View/download PDF

21. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe

Author: Leonardo Salese, James Lucas, Daniel Bluff, M. Tarallo, Joseph C. Cappelleri, Danielle Bargo, Benjamin Hoskin, Alessandro Armuzzi, Daniel Quirk, and Marco DiBonaventura
Subjects: Male, Medical Doctors, Economics, Health Care Providers, Social Sciences, Infographics, Geographical locations, Steroid Therapy, 0302 clinical medicine, Medicine and Health Sciences, Medicine, Medical Personnel, media_common, Multidisciplinary, Pharmaceutics, Disease Management, Middle Aged, Colitis, Charts, Ulcerative colitis, Europe, Professions, Drug Combinations, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, Research Article, medicine.drug, Adult, Computer and Information Sciences, medicine.medical_specialty, Combination therapy, Science, MEDLINE, Gastroenterology and Hepatology, 03 medical and health sciences, Drug Therapy, Gastrointestinal Agents, Physicians, Internal medicine, Adalimumab, Ulcerative Colitis, Humans, media_common.cataloged_instance, European Union, European union, Dose-Response Relationship, Drug, business.industry, Data Visualization, Inflammatory Bowel Disease, medicine.disease, United States, Infliximab, Health Care, Concomitant, People and Places, North America, Population Groupings, Colitis, Ulcerative, business, Finance
Abstract: Objective The aim of the present study is to examine how moderate-to-severe ulcerative colitis (UC) is currently managed in real-world clinical practice across the United States (US) and European Union Five (EU5; France, Germany, Italy, Spain, and the United Kingdom). Methods Data from the 2017 Adelphi Inflammatory Bowel-Disease Specific Programme (IBD-DSP) were used. The IBD-DSP is a database of patient chart information abstracted by selected gastroenterologists across the US and EU5. Eligible gastroenterologists who agreed to participate were asked to complete patient record forms for the next seven consecutive eligible adult patients with UC. Only charts from patients with moderate-to-severe UC were included in the analysis (defined as those with documented administration of either an immunosuppressant [IM] or a biologic). Treatment patterns were reported descriptively. Results 411 and 1191 patient charts were included in the US and EU5 (mean ages 44.2 and 39.6 years; 53.0% and 43.5% female), respectively. For those with complete treatment history, 40.7% and 52.9% used either an IM or biologic as their first treatment (with or without steroids). Usage of these therapies increased in subsequent lines. The percentage of patients treated with combination therapy (i.e., biologic therapy with a concomitant IM) in first line generally varied between 10–20% (e.g., US: adalimumab (ADA), 10.8%; infliximab (IFX), 18.2%; EU5: ADA, 12.5%; IFX, 19.9%), though increased in later lines in the EU5. Among patients currently using a biologic therapy, between 10–40% of patients used a higher than indicated dose or greater than indicated dosing frequency during maintenance (e.g., US: IFX, 37.1%; ADA, 13.4%; EU5: IFX, 39.1%; ADA, 36.1%). In both the US and EU5, the primary reason for switching therapy was efficacy-related. Conclusions In this analysis, many patients with moderate-to-severe UC use an IM or biologic as their first therapy after diagnosis. Combination therapy and dose escalation are also common, and underscore the challenges with managing this patient population.
Published: 2020
Full Text: View/download PDF

22. Budget Impact of Etanercept Versus Adalimumab for Treatment of Rheumatoid Arthritis In Biologic-Naïve Patients in the United Kingdom

Author: C Curiale, M. Tarallo, Kateryna Onishchenko, and ST Alexopoulos
Subjects: medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Budget impact, medicine.disease, Etanercept, Therapy naive, Rheumatoid arthritis, Internal medicine, medicine, Adalimumab, business, medicine.drug
Published: 2018
Full Text: View/download PDF

23. PBI81 PERSISTENCE AND HEALTHCARE RESOURCE USE (HCRU) IN PATIENTS INITIATING ETANERCEPT TREATMENT FOR ANKYLOSING SPONDYLITIS (AS) OR PSORIATIC ARTHRITIS (PSA) IN GERMANY: A REAL-WORLD ANALYSIS

Author: Xenofon Baraliakos, O. Behmer, A.C. Hernandez Daly, D. Poddubnyy, Joseph C. Cappelleri, Frank Behrens, Cinzia Curiale, N. Hudson, M. Tarallo, and C. Gray
Subjects: Persistence (psychology), Ankylosing spondylitis, medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine.disease, Etanercept, Psoriatic arthritis, Internal medicine, Health care, medicine, Resource use, In patient, business, medicine.drug
Published: 2019
Full Text: View/download PDF

24. New lift: the art of facial rejuvenation with minimal incisions rhytidectomy

Author: M, Tarallo, M, Toscani, G, Di Taranto, V, Sorvillo, and P, Fino
Subjects: Adult, Cheek, Treatment Outcome, Esthetics, Rhytidoplasty, Humans, Minimally Invasive Surgical Procedures, Rejuvenation, Middle Aged
Abstract: The new lift is a procedure for facial rejuvenation with minimal incision, giving the patient a significant improvement of mid face and neck, with limited dissection and minimal scars. A further "One-stitch" of anchorage to the deep temporal fascia is required to hold tissues. By a minimal surgical access, we get a suitable cheek lift with the improvement of nose-labial folds, mandibular edge and neck contour.Between February 2009 and June 2012, 32 patients underwent facial rejuvenation surgery called new lift at a mean age of 46 years (range 35-55 years). Seven of the patients had a previous facelift. 12 out of 32 patients (37.5%) had concomitant eyelid surgery and 4 (12.5%) neck contouring procedure.The technique we used is a safe and effective procedure with a high satisfaction rate; 28 patients (89%) were very satisfied with their result at 24-months follow-up.The surgical outcome was evaluated according to the analysis of photographs obtained before and after surgery and the analysis of pre- and postoperative measurements. Aesthetic results were evaluated also by patients themselves who indicated a high satisfaction rate at three months post-surgery questionary and by a surgeon not involved in the study using VAS (1-10) before and three months after surgery. Acquired data on the aesthetic result were statistically evaluated using Student t-test. This is a study aimed at assessing the effectiveness of the new-lift technique for facial rejuvenation. Based on the results of our study, the new-lift is a very effective surgery for rejuvenation of the face with mild to moderate aging. All patients healed uneventfully without any major postoperative problems. This technique responds to an increasing demand from a wide range of patients for less invasive, less expensive operations with faster healing time and fewer potential complications.
Published: 2016

25. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective

Author: Jose Alvir, M. Tarallo, Peter C. Taylor, Adam W. Moore, and Radu Vasilescu
Subjects: medicine.medical_specialty, Cost, Review Article - Review on Disease, Immunology, MEDLINE, Alternative medicine, Pain, PsycINFO, EconLit, Arthritis, Rheumatoid, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Cost of Illness, Rheumatology, Internal medicine, Medicine, Humans, Immunology and Allergy, 030212 general & internal medicine, Rheumatoid arthritis, Psychiatry, Fatigue, 030203 arthritis & rheumatology, Health Services Needs and Demand, business.industry, Mental functioning, medicine.disease, Systematic review, Family medicine, Quality of Life, business, Physical functioning
Abstract: While rheumatologists often focus on treatment targets, for many patients with rheumatoid arthritis (RA), control over pain and fatigue, as well as sustaining physical function and quality of life (QoL), is of primary importance. This literature review aimed at examining patients' and physicians' treatment aspirations, and identifying the unmet needs for patients with RA receiving ongoing treatment. Searches were performed using MEDLINE, Embase, PsycINFO, and Econlit literature databases for articles published from 2004 to 2014 in the English language. Published literature was screened to identify articles reporting the unmet needs in RA. We found that, despite the wide range of available treatments, RA continues to pose a substantial humanistic and economic burden on patients, and there are still unmet needs across key domains such as pain, physical function, mental function, and fatigue. These findings suggest that there is a need for further treatment advances in RA that address these domains of contemporary unmet need.
Published: 2016

26. 057 Comparison of Biologic Disease-Modifying Anti-Rheumatic Drug Rheumatoid Arthritis Treatment Dynamics Across Five European Union Countries

Author: Juan J. Gomez-Reino, Roberto Caporali, Philippe Bertin, Peter C. Taylor, Emma Sullivan, Jose Alvir, Dean Spurden, M. Tarallo, James Piercy, Rieke Alten, Radu Vasilescu, and Robert Wood
Subjects: 030203 arthritis & rheumatology, medicine.medical_specialty, business.industry, Anti rheumatic drugs, Disease, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Rheumatoid arthritis, medicine, media_common.cataloged_instance, 030212 general & internal medicine, European union, business, media_common
Published: 2016
Full Text: View/download PDF

27. Resource Utilization and Cost of Treatment with Anidulafungin or Fluconazole for Candidaemia and Other Forms of Invasive Candidiasis

Author: Daniel H. Kett, M. Tarallo, Richard Chambers, Coleman Rotstein, Shannon Cartier, Annette C. Reboli, and Michael Maschio
Subjects: Male, Antifungal Agents, Anidulafungin, Echinocandins, chemistry.chemical_compound, jel:I1, polycyclic compounds, Hospital Costs, Fluconazole, Randomized Controlled Trials as Topic, jel:Z, Health Policy, Invasive candidiasis, Middle Aged, jel:I11, Hospitalization, Intensive Care Units, jel:I18, jel:I19, Health Resources, Regression Analysis, Female, medicine.drug, Adult, medicine.medical_specialty, Critical Illness, jel:D, jel:C, jel:I, Drug Costs, Double-Blind Method, medicine, Humans, Anidulafungin, Antifungals, Candidaemia, Candidiasis, Cost-analysis, Fluconazole, Candidiasis, Invasive, Intensive care medicine, Aged, Retrospective Studies, Pharmacology, business.industry, Public Health, Environmental and Occupational Health, Micafungin, Candidemia, Retrospective cohort study, Length of Stay, bacterial infections and mycoses, medicine.disease, Clinical trial, Clinical Trials, Phase III as Topic, chemistry, Caspofungin, business
Abstract: Background: Candidaemia and other forms of invasive candidiasis (C/IC) are serious and costly events for hospitalized patients, particularly those in the ICU. Both fluconazole and the echinocandins are recommended as first-line therapy for C/IC. Resource use and cost considerations are important in selecting appropriate treatment but little information is available on the economic implications of using echinocandins in this setting. Objective: To compare resource utilization and treatment costs (in &dollar;US) associated with the echinocandin anidulafungin (200 mg intravenously on day 1, then 100 mg intravenously daily) versus those of fluconazole (800 mg intravenously on day 1, then 400 mg intravenously daily) as first-line treatment for C/IC. Methods: Available charts from patients enrolled in a recent clinical trial comparing anidulafungin and fluconazole for C/IC were reviewed. Patients who were in the ICU at study entry were identified, and the following data, collected during the 13-week study period, were compared between treatment groups: global response at end of study treatment, number of days patients survived after hospital discharge ('hospital-free' days), hospital resource use, and C/IC-related costs (year 2008 values) to a US hospital payer. These comparisons were also conducted for all non-ICU hospitalized patients, and for survivors in both study populations. Sensitivity analyses explored the cost impact of variability in the hospitalization costs between ICUs and non-ICU wards and of reduced duration intravenous therapy. Statistical comparisons between the two treatment groups were conducted for clinical outcomes, resource use and cost measures, using regression models. All statistical comparisons were adjusted for baseline co-variates (Acute Physiology and Chronic Health Evaluation [APACHE] II score, absolute neutrophil count and catheter removal status). Results: For ICU patients with C/IC (n - 63), global response was significantly higher for anidulafungin than fluconazole (68.6% vs 42.9%; p - 0.03). ICU patients treated with anidulafungin had an average of 13.9 more hospital-free days (18.2 vs 4.3 days; p - 0.04) than those treated with fluconazole. After adjustment for co-variates, although lower costs were observed for anidulafungin vs fluconazole in ICU patients and in ICU patients who survived, no statistical differences were found. For all hospitalized patients (n - 159), global response was also higher for anidulafungin (78.3% vs 60.5%; p < 0.01). There was no difference in average length of hospitalization (29.6 days) or hospital-free days. After adjustment for co-variates, anidulafungin treatment resulted in an incremental C/IC-related cost of &dollar;US2680 (p - 0.73). For hospitalized patients who survived (anidulafungin 81.9%, fluconazole 69.7%), anidulafungin treatment was associated with an incremental cost of &dollar;US231 (p - 0.98). Conclusion: Anidulafungin as first-line treatment of C/IC appears to be of particular benefit to ICU patients, improving clinical outcomes and possibly decreasing costs, driven by reduced ICU and hospital stay, when compared with fluconazole. Anidulafungin also yielded significantly improved treatment outcomes in the general inpatient population, with total costs similar to fluconazole.
Published: 2011
Full Text: View/download PDF

28. Cost and Resource Utilization Associated With Fluconazole as First-Line Therapy for Invasive Candidiasis: A Retrospective Database Analysis

Author: Christopher M. Blanchette, Frank R. Ernst, M. Tarallo, Christopher Craver, and Craig S. Roberts
Subjects: Male, medicine.medical_specialty, Antifungal Agents, Databases, Factual, Cost-Benefit Analysis, MEDLINE, law.invention, Pharmacotherapy, law, Internal medicine, medicine, Humans, Candidiasis, Invasive, Pharmacology (medical), Intensive care medicine, Fluconazole, Mycosis, Fungemia, Retrospective Studies, Pharmacology, business.industry, Mortality rate, Retrospective cohort study, Health Care Costs, Middle Aged, medicine.disease, Intensive care unit, Drug Utilization, Female, business, medicine.drug
Abstract: Background Fluconazole is a standard first-line therapy for candidemia/invasive candidiasis (C/IC), based on its efficacy, safety profile, and comparatively low acquisition cost. However, little is known about the total costs associated with fluconazole treatment for this indication, particularly in cases of clinical failure. Objective The aim of this study was to examine overall costs, resource use, and treatment outcomes associated with fluconazole as first-line therapy for invasive Candida infections in the United States. Methods A retrospective analysis of data from a US hospital-based (>500 hospitals), service-level database was performed. All patients aged >16 years with primary or secondary International Classification of Diseases, Ninth Revision, Clinical Modification codes for IC or septicemia, receiving intravenous fluconazole treatment, and discharged between October 1, 2004 and September 30, 2005 were selected. Costs and resource use were calculated from the start of antifungal therapy until discharge. Two groups were analyzed: patients who received fluconazole only and those who required a second-line antifungal. Separate analyses for the survivor subpopulations were also conducted. Results A total of 7170 patients met the inclusion criteria; 21.2% required an additional antifungal agent. Overall mortality was 27.1%, and total mean treatment cost for all patients was $44,482 (in 2005 US dollars). Patients treated with fluconazole alone incurred mean costs of $36,319. Mean hospital and intensive care unit stays in the fluconazole monotherapy group were 17.9 days and 7.1 days, respectively. Patients requiring additional therapy had a mortality rate of 34.5% and a mean treatment cost of $76,329; in this group, the mean hospital and intensive care unit stays were 31.7 days and 14.8 days, respectively. Conclusions The overall resource use associated with fluconazole as first-line treatment for C/IC was high, especially in patients who required additional antifungal therapy. Future studies should examine the patterns of care and costs associated with alternative treatment options as first-line C/IC therapy.
Published: 2010
Full Text: View/download PDF

29. PRM42 - COST MODEL OF SWITCHING FROM ENBREL TO ETANERCEPT BIOSIMILARS, FOR NON MEDICAL REASONS, IN RHEUMATOID ARTHRITIS PATIENTS IN SPAIN

Author: María Montoro, S. Gómez, M Tarallo, C. Peral, and M. Valderrama
Subjects: medicine.medical_specialty, business.industry, Health Policy, Rheumatoid arthritis, Public Health, Environmental and Occupational Health, medicine, Biosimilar, medicine.disease, business, Dermatology, Etanercept, medicine.drug
Published: 2018
Full Text: View/download PDF

30. Data quality studies for burst analysis of Virgo data acquired during Weekly Science Runs

Author: F Acernese, P Amico, M Alshourbagy, F Antonucci, S Aoudia, P Astone, S Avino, D Babusci, G Ballardin, F Barone, L Barsotti, M Barsuglia, Th S Bauer, F Beauville, S Bigotta, S Birindelli, M A Bizouard, C Boccara, F Bondu, L Bosi, C Bradaschia, S Braccini, F J van den Brand, A Brillet, V Brisson, D Buskulic, E Calloni, E Campagna, F Carbognani, F Cavalier, R Cavalieri, G Cella, E Cesarini, E Chassande-Mottin, N Christensen, C Corda, A Corsi, F Cottone, A-C Clapson, F Cleva, J-P Coulon, E Cuoco, A Dari, V Dattilo, M Davier, M del Prete, R De Rosa, L Di Fiore, A Di Virgilio, B Dujardin, A Eleuteri, M Evans, I Ferrante, F Fidecaro, I Fiori, R Flaminio, J-D Fournier, S Frasca, F Frasconi, L Gammaitoni, F Garufi, E Genin, A Gennai, A Giazotto, G Giordano, L Giordano, R Gouaty, D Grosjean, G Guidi, S Hamdani, S Hebri, H Heitmann, P Hello, D Huet, S Karkar, S Kreckelbergh, P La Penna, M Laval, N Leroy, N Letendre, B Lopez, null Lorenzini, V Loriette, G Losurdo, J-M Mackowski, E Majorana, C N Man, M Mantovani, F Marchesoni, F Marion, J Marque, F Martelli, A Masserot, M Mazzoni, L Milano, F Menzinger, C Moins, J Moreau, N Morgado, B Mours, F Nocera, C Palomba, F Paoletti, S Pardi, A Pasqualetti, R Passaquieti, D Passuello, F Piergiovanni, L Pinard, R Poggiani, M Punturo, P Puppo, S van der Putten, K Qipiani, P Rapagnani, V Reita, A Remillieux, F Ricci, I Ricciardi, P Ruggi, G Russo, S Solimeno, A Spallicci, M Tarallo, M Tonelli, A Toncelli, E Tournefier, F Travasso, C Tremola, G Vajente, D Verkindt, F Vetrano, A Viceré, J-Y Vinet, H Vocca, M Yvert, DE ROSA, Rosario, Garufi, Fabio, Milano, Leopoldo, Calloni, Enrico, Avino, Saverio, F., Acernese, Solimeno, Salvatore, Giordano, Lara, Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux ( ARTEMIS ), Université Nice Sophia Antipolis ( UNS ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Observatoire de la Côte d'Azur, Université Côte d'Azur ( UCA ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de l'Accélérateur Linéaire ( LAL ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire d'Annecy de Physique des Particules ( LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules ), Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Université Savoie Mont Blanc ( USMB [Université de Savoie] [Université de Chambéry] ) -Centre National de la Recherche Scientifique ( CNRS ), ESPCI ParisTech, APC - Gravitation ( APC-Gravitation ), AstroParticule et Cosmologie ( APC - UMR 7164 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Observatoire de Paris-Université Paris Diderot - Paris 7 ( UPD7 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Observatoire de Paris-Université Paris Diderot - Paris 7 ( UPD7 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Max-Planck-Institut für Gravitationsphysik (Albert-Einstein-Institut), Max-Planck-Institut-Max-Planck-Institut, Laboratoire des matériaux avancés ( LMA ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Virgo, Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), VIRGO, Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux (ARTEMIS), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de l'Accélérateur Linéaire (LAL), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL), APC - Gravitation (APC-Gravitation), AstroParticule et Cosmologie (APC (UMR_7164)), Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Max-Planck-Gesellschaft-Max-Planck-Gesellschaft, Laboratoire des matériaux avancés (LMA), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), and Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Physics, Physics and Astronomy (miscellaneous), 010308 nuclear & particles physics, Event (computing), Gravitational wave, Detector, Real-time computing, 01 natural sciences, [ PHYS.GRQC ] Physics [physics]/General Relativity and Quantum Cosmology [gr-qc], Task (computing), Data quality, 0103 physical sciences, Environmental monitoring, [PHYS.GRQC]Physics [physics]/General Relativity and Quantum Cosmology [gr-qc], Waveform, Noise (video), 010306 general physics
Abstract: International audience; Virgo started collecting science data during weekends in order to not interfere with commissioning activities. The goal of Weekly Science Runs is to ease the transition between commissioning periods and data taking periods, in addition to providing data sets exploiting the stationary behavior of the detector. The detection of gravitational wave (GW) bursts emitted by core collapse of supernovae is one of the most difficult tasks for the GW community due to the fact that there are uncertainties in the exact shape of the waveforms, as we do not have complete models. A major task for this kind of detection effort is the cleaning of the event triggers found by the detection pipelines, namely the removal of accidental transient signals due to noise source events. In order to clean our data from false GW events, we need to define a strategy for data quality cut and veto of auxiliary and environmental monitoring channels. In this paper we report on the analysis we performed on data acquired during Weekly Science Runs to explore and define the data quality cut and veto studies for burst analysis.
Published: 2007
Full Text: View/download PDF

31. Status of Virgo

Author: F Acernese, M Alshourbagy, P Amico, F Antonucci, S Aoudia, P Astone, S Avino, L Baggio, G Ballardin, F Barone, L Barsotti, M Barsuglia, Th S Bauer, S Bigotta, S Birindelli, M A Bizouard, C Boccara, F Bondu, L Bosi, S Braccini, C Bradaschia, A Brillet, V Brisson, D Buskulic, G Cagnoli, E Calloni, E Campagna, F Carbognani, F Cavalier, R Cavalieri, G Cella, E Cesarini, E Chassande-Mottin, A-C Clapson, F Cleva, E Coccia, C Corda, A Corsi, F Cottone, J-P Coulon, E Cuoco, S D'Antonio, A Dari, V Dattilo, M Davier, R De Rosa, M Del Prete, L Di Fiore, A Di Lieto, M Di Paolo Emilio, A Di Virgilio, M Evans, V Fafone, I Ferrante, F Fidecaro, I Fiori, R Flaminio, J-D Fournier, S Frasca, F Frasconi, L Gammaitoni, F Garufi, E Genin, A Gennai, A Giazotto, L Giordano, V Granata, C Greverie, D Grosjean, G Guidi, S Hamdani, S Hebri, H Heitmann, P Hello, D Huet, S Kreckelbergh, P La Penna, M Laval, N Leroy, N Letendre, B Lopez, M Lorenzini, V Loriette, G Losurdo, J-M Mackowski, E Majorana, C N Man, M Mantovani, F Marchesoni, F Marion, J Marque, F Martelli, A Masserot, F Menzinger, L Milano, Y Minenkov, C Moins, J Moreau, N Morgado, S Mosca, B Mours, I Neri, F Nocera, G Pagliaroli, C Palomba, F Paoletti, S Pardi, A Pasqualetti, R Passaquieti, D Passuello, F Piergiovanni, L Pinard, R Poggiani, M Punturo, P Puppo, P Rapagnani, T Regimbau, A Remillieux, F Ricci, I Ricciardi, A Rocchi, L Rolland, R Romano, P Ruggi, G Russo, S Solimeno, A Spallicci, M Tarallo, R Terenzi, A Toncelli, M Tonelli, E Tournefier, F Travasso, C Tremola, G Vajente, J F J van den Brand, S van der Putten, D Verkindt, F Vetrano, A Viceré, J-Y Vinet, H Vocca, M Yvert, (Astro)-Particles Physics, Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux ( ARTEMIS ), Université Nice Sophia Antipolis ( UNS ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Observatoire de la Côte d'Azur, Université Côte d'Azur ( UCA ) -Centre National de la Recherche Scientifique ( CNRS ), APC - Cosmologie, Physique Corpusculaire et Cosmologie - Collège de France ( PCC ), Collège de France ( CdF ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS ) -Collège de France ( CdF ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS ) -AstroParticule et Cosmologie ( APC - UMR 7164 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Observatoire de Paris-Université Paris Diderot - Paris 7 ( UPD7 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Centre National de la Recherche Scientifique ( CNRS ) -Observatoire de Paris-Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ), Laboratoire de l'Accélérateur Linéaire ( LAL ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), ESPCI ParisTech, Laboratoire d'Annecy de Physique des Particules ( LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules ), Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Université Savoie Mont Blanc ( USMB [Université de Savoie] [Université de Chambéry] ) -Centre National de la Recherche Scientifique ( CNRS ), APC - Gravitation ( APC-Gravitation ), AstroParticule et Cosmologie ( APC - UMR 7164 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Observatoire de Paris-Université Paris Diderot - Paris 7 ( UPD7 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Observatoire de Paris-Université Paris Diderot - Paris 7 ( UPD7 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Max-Planck-Institut für Gravitationsphysik (Albert-Einstein-Institut), Max-Planck-Institut-Max-Planck-Institut, Laboratoire des matériaux avancés ( LMA ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Virgo, Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), VIRGO, Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux (ARTEMIS), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), AstroParticule et Cosmologie (APC (UMR_7164)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de l'Accélérateur Linéaire (LAL), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), APC - Gravitation (APC-Gravitation), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Max-Planck-Gesellschaft-Max-Planck-Gesellschaft, Laboratoire des matériaux avancés (LMA), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), F., Acernese, M., Alshourbagy, P., Amico, F., Antonucci, S., Aoudia, P., Astone, S., Avino, L., Baggio, G., Ballardin, F., Barone, L., Barsotti, M., Barsuglia, Th S., Bauer, S., Bigotta, S., Birindelli, M. A., Bizouard, C., Boccara, F., Bondu, L., Bosi, S., Braccini, C., Bradaschia, A., Brillet, V., Brisson, D., Buskulic, G., Cagnoli, Calloni, Enrico, E., Campagna, F., Carbognani, F., Cavalier, R., Cavalieri, G., Cella, E., Cesarini, E., Chassande Mottin, A. C., Clapson, F., Cleva, E., Coccia, C., Corda, A., Corsi, F., Cottone, J. P., Coulon, E., Cuoco, S., D'Antonio, A., Dari, V., Dattilo, M., Davier, DE ROSA, Rosario, M., Del Prete, L., Di Fiore, A., Di Lieto, M., Di Paolo Emilio, A., Di Virgilio, M., Evan, V., Fafone, I., Ferrante, F., Fidecaro, I., Fiori, R., Flaminio, J. D., Fournier, S., Frasca, F., Frasconi, L., Gammaitoni, Garufi, Fabio, E., Genin, A., Gennai, A., Giazotto, L., Giordano, V., Granata, C., Greverie, D., Grosjean, G., Guidi, S., Hamdani, S., Hebri, H., Heitmann, P., Hello, D., Huet, S., Kreckelbergh, P., La Penna, M., Laval, N., Leroy, N., Letendre, B., Lopez, M., Lorenzini, V., Loriette, G., Losurdo, J. M., Mackowski, E., Majorana, C. N., Man, M., Mantovani, F., Marchesoni, F., Marion, J., Marque, F., Martelli, A., Masserot, F., Menzinger, Milano, Leopoldo, Y., Minenkov, C., Moin, J., Moreau, N., Morgado, S., Mosca, B., Mour, I., Neri, F., Nocera, G., Pagliaroli, C., Palomba, F., Paoletti, S., Pardi, A., Pasqualetti, R., Passaquieti, D., Passuello, F., Piergiovanni, L., Pinard, R., Poggiani, M., Punturo, P., Puppo, P., Rapagnani, T., Regimbau, A., Remillieux, F., Ricci, I., Ricciardi, A., Rocchi, L., Rolland, R., Romano, P., Ruggi, Russo, Guido, Solimeno, Salvatore, A., Spallicci, M., Tarallo, R., Terenzi, A., Toncelli, M., Tonelli, E., Tournefier, F., Travasso, C., Tremola, G., Vajente, J. F. J., van den Brand, S., van der Putten, D., Verkindt, F., Vetrano, A., Viceré, J. Y., Vinet, H., Vocca, M., Yvert, Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Physique Corpusculaire et Cosmologie - Collège de France (PCC), Collège de France (CdF)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Collège de France (CdF)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-AstroParticule et Cosmologie (APC (UMR_7164)), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7), Laboratoire d'Annecy de Physique des Particules (LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules), PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), and Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Gravitational-wave observatory, Physics and Astronomy (miscellaneous), [SDU.ASTR.CO]Sciences of the Universe [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], Physics::Instrumentation and Detectors, Astrophysics, Astrophysics::Cosmology and Extragalactic Astrophysics, [ PHYS.ASTR.CO ] Physics [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], 7. Clean energy, 01 natural sciences, [PHYS.ASTR.CO]Physics [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], 0103 physical sciences, Binary star, Astronomical interferometer, 010303 astronomy & astrophysics, [ SDU.ASTR ] Sciences of the Universe [physics]/Astrophysics [astro-ph], Physics, [SDU.ASTR]Sciences of the Universe [physics]/Astrophysics [astro-ph], 010308 nuclear & particles physics, Gravitational wave, Detector, Settore FIS/01 - Fisica Sperimentale, Astrophysics::Instrumentation and Methods for Astrophysics, Astronomy, Neutron star, Upgrade, Duty cycle, [ SDU.ASTR.CO ] Sciences of the Universe [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], Physics::Accelerator Physics
Abstract: International audience; The Virgo detector has now finished its first science run; a science mode duty cycle of more than 80% and a 4.5 Mpc horizon distance for binary neutron star inspiral sources were achieved. Commissioning breaks were organized during the run which permitted improvement of the sensitivity and the robustness of the interferometer against environmental perturbations like bad weather and earthquakes. The post-run commissioning phase has now started, with the goal of preparing the next upgrade step of the detector, Virgo+.
Published: 2008
Full Text: View/download PDF

32. Status of coalescing binaries search activities in Virgo

Author: F Acernese, P Amico, M Alshourbagy, F Antonucci, S Aoudia, P Astone, S Avino, D Babusci, G Ballardin, F Barone, L Barsotti, M Barsuglia, Th S Bauer, F Beauville, S Bigotta, S Birindelli, M A Bizouard, C Boccara, F Bondu, L Bosi, C Bradaschia, S Braccini, J F J van den Brand, A Brillet, V Brisson, D Buskulic, E Calloni, E Campagna, F Carbognani, F Cavalier, R Cavalieri, G Cella, E Cesarini, E Chassande-Mottin, N Christensen, C Corda, A Corsi, F Cottone, A-C Clapson, F Cleva, J-P Coulon, E Cuoco, A Dari, V Dattilo, M Davier, M del Prete, R De Rosa, L Di Fiore, A Di Virgilio, B Dujardin, A Eleuteri, M Evans, I Ferrante, F Fidecaro, I Fiori, R Flaminio, J-D Fournier, S Frasca, F Frasconi, L Gammaitoni, F Garufi, E Genin, A Gennai, A Giazotto, G Giordano, L Giordano, R Gouaty, D Grosjean, G Guidi, S Hamdani, S Hebri, H Heitmann, P Hello, D Huet, S Karkar, S Kreckelbergh, P La Penna, M Laval, N Leroy, N Letendre, B Lopez, null Lorenzini, V Loriette, G Losurdo, J-M Mackowski, E Majorana, C N Man, M Mantovani, F Marchesoni, F Marion, J Marque, F Martelli, A Masserot, M Mazzoni, L Milano, F Menzinger, C Moins, J Moreau, N Morgado, B Mours, F Nocera, C Palomba, F Paoletti, S Pardi, A Pasqualetti, R Passaquieti, D Passuello, F Piergiovanni, L Pinard, R Poggiani, M Punturo, P Puppo, S van der Putten, K Qipiani, P Rapagnani, V Reita, A Remillieux, F Ricci, I Ricciardi, P Ruggi, G Russo, S Solimeno, A Spallicci, M Tarallo, M Tonelli, A Toncelli, E Tournefier, F Travasso, C Tremola, G Vajente, D Verkindt, F Vetrano, A Viceré, J-Y Vinet, H Vocca, M Yvert, Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux (ARTEMIS), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de l'Accélérateur Linéaire (LAL), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL), APC - Gravitation (APC-Gravitation), AstroParticule et Cosmologie (APC (UMR_7164)), Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Max-Planck-Gesellschaft-Max-Planck-Gesellschaft, Laboratoire des matériaux avancés (LMA), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Virgo, Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), VIRGO, Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules), ESPCI ParisTech, Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Geometry, (Astro)-Particles Physics, Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Girod, Dominique, F., Acernese, P., Amico, M., Alshourbagy, F., Antonucci, S., Aoudia, P., Astone, Avino, Saverio, D., Babusci, G., Ballardin, F., Barone, L., Barsotti, M., Barsuglia, Th S., Bauer, F., Beauville, S., Bigotta, S., Birindelli, M. A., Bizouard, C., Boccara, F., Bondu, L., Bosi, C., Bradaschia, S., Braccini, J. F. J., van den Brand, A., Brillet, V., Brisson, D., Buskulic, Calloni, Enrico, E., Campagna, F., Carbognani, F., Cavalier, R., Cavalieri, G., Cella, E., Cesarini, E., Chassande Mottin, N., Christensen, C., Corda, A., Corsi, F., Cottone, A. C., Clapson, F., Cleva, J. P., Coulon, E., Cuoco, A., Dari, V., Dattilo, M., Davier, M., del Prete, DE ROSA, Rosario, L., Di Fiore, A., Di Virgilio, B., Dujardin, Eleuteri, Antonio, M., Evan, I., Ferrante, F., Fidecaro, I., Fiori, R., Flaminio, J. D., Fournier, S., Frasca, F., Frasconi, L., Gammaitoni, Garufi, Fabio, E., Genin, A., Gennai, A., Giazotto, G., Giordano, Giordano, Lara, R., Gouaty, D., Grosjean, G., Guidi, S., Hamdani, S., Hebri, H., Heitmann, P., Hello, D., Huet, S., Karkar, S., Kreckelbergh, P., La Penna, M., Laval, N., Leroy, N., Letendre, B., Lopez, Lorenzini, V., Loriette, G., Losurdo, J. M., Mackowski, E., Majorana, C. N., Man, M., Mantovani, F., Marchesoni, F., Marion, J., Marque, F., Martelli, A., Masserot, M., Mazzoni, Milano, Leopoldo, F., Menzinger, C., Moin, J., Moreau, N., Morgado, B., Mour, F., Nocera, C., Palomba, F., Paoletti, Pardi, Silvio, A., Pasqualetti, R., Passaquieti, D., Passuello, F., Piergiovanni, L., Pinard, R., Poggiani, M., Punturo, P., Puppo, S., van der Putten, K., Qipiani, P., Rapagnani, V., Reita, A., Remillieux, F., Ricci, I., Ricciardi, P., Ruggi, Russo, Guido, Solimeno, Salvatore, A., Spallicci, M., Tarallo, M., Tonelli, A., Toncelli, E., Tournefier, F., Travasso, C., Tremola, G., Vajente, D., Verkindt, F., Vetrano, A., Viceré, J. Y., Vinet, H., Vocca, and M., Yvert
Subjects: Online and offline, Physics and Astronomy (miscellaneous), [SDU.ASTR.CO]Sciences of the Universe [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], Pipeline (computing), Binary number, [SDU.ASTR] Sciences of the Universe [physics]/Astrophysics [astro-ph], 01 natural sciences, GRAVITATIONAL-WAVES, Computational science, [PHYS.ASTR.CO]Physics [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], Advanced phase, 0103 physical sciences, 04.80.Nn, 95.55.Ym, Interferometric gravitational wave detector, [PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det], 010306 general physics, DETECTOR, ComputingMilieux_MISCELLANEOUS, Physics, [SDU.ASTR]Sciences of the Universe [physics]/Astrophysics [astro-ph], 010308 nuclear & particles physics, Estimation theory, Gravitational wave, Detector, Astrophysics::Instrumentation and Methods for Astrophysics, Astronomy, [PHYS.ASTR.CO] Physics [physics]/Astrophysics [astro-ph]/Cosmology and Extra-Galactic Astrophysics [astro-ph.CO], [PHYS.PHYS.PHYS-INS-DET] Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det]
Abstract: The interferometric gravitational wave detector Virgo is undergoing an advanced phase of its commissioning, during which short runs are routinely performed, in which data are analyzed online and offline, searching for signals from coalescing binary systems. In this report we present the progress of the coalescing binaries search activities in Virgo, and we describe details of the detection pipeline including hardware injections, vetoes, and parameter estimation, using recent data taking. © 2007 IOP Publishing Ltd.
Published: 2007
Full Text: View/download PDF

33. Improvement in Disease Activity Scores Associated with Early Versus Late Initiation of Biologic Therapy in Patients with Rheumatoid Arthritis: Results of a European Chart Review Study

Author: Caitlyn T. Solem, Joseph C. Cappelleri, Paul Emery, Istvan M. Majer, M. Tarallo, C.P. Macahilig, and Jennifer Stephens
Subjects: medicine.medical_specialty, business.industry, Health Policy, Public Health, Environmental and Occupational Health, medicine.disease, Surgery, Disease activity, Rheumatoid arthritis, Chart review, Internal medicine, medicine, In patient, business, Late initiation
Published: 2013
Full Text: View/download PDF

34. Rationale for Initiating and Switching Biologic Therapy in Patients with Rheumatoid Arthritis: Results of a European Chart Review Study

Author: M. B. McGuire, Paul Emery, Shelby Corman, M. Tarallo, Istvan M. Majer, Joseph C. Cappelleri, Caitlyn T. Solem, and Cynthia Macahilig
Subjects: medicine.medical_specialty, business.industry, Rheumatoid arthritis, Chart review, Health Policy, Physical therapy, Public Health, Environmental and Occupational Health, Medicine, In patient, business, medicine.disease, Intensive care medicine
Published: 2013
Full Text: View/download PDF

35. A Model to Evaluate the Immunogenicity Costs of Tumour Necrosis Factor-Alpha Inhibitors in Patients with Rheumatoid Arthritis

Author: Istvan M. Majer, Bart Heeg, Jennifer Stephens, and M. Tarallo
Subjects: business.industry, Immunogenicity, Rheumatoid arthritis, Health Policy, Immunology, Public Health, Environmental and Occupational Health, Medicine, In patient, Tumour necrosis factor alpha, business, medicine.disease
Published: 2013
Full Text: View/download PDF

36. Association between drug tolerability and medical resource use in prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplant

Author: Xin Gao, X. Ji, M. Tarallo, J M Stephens, Haran T. Schlamm, and D I Marks
Subjects: Drug, Adult, Male, medicine.medical_specialty, Antifungal Agents, Adolescent, Itraconazole, medicine.medical_treatment, media_common.quotation_subject, Hematopoietic stem cell transplantation, Young Adult, Internal medicine, Medicine, Humans, Young adult, Child, media_common, Aged, Randomized Controlled Trials as Topic, Retrospective Studies, Voriconazole, business.industry, Health Policy, Hematopoietic Stem Cell Transplantation, Retrospective cohort study, Antibiotic Prophylaxis, Health Services, Middle Aged, Triazoles, Discontinuation, Surgery, Hospitalization, Pyrimidines, Tolerability, Mycoses, Female, business, medicine.drug
Abstract: To conduct a retrospective analysis of the association between drug tolerability and potential economic impact measured by medical resource utilization (MRU) for prophylaxis of invasive antifungal infections (IFI) after allogeneic hematopoietic stem cell transplantation (alloHCT).An open-label, multi-center study (IMPROVIT) included patients (≥12-years old) who were randomized to receive oral voriconazole (VOR) or oral itraconazole (ITR) from the alloHCT day for at least 100 days and up to 180 days. Trial data on discontinuation and MRU for the first 100 days were analyzed.Two hundred and twenty-four patients were in VOR and 241 in ITR, with similar demographic distributions (average age of 43 years, 58% male, 92% Caucasian). All-cause and study drug intolerance discontinuations were less frequent with VOR than ITR (50% vs 63%, p = 0.0137; 7% vs 22%, p 0.0001). VOR patients had longer study drug exposure (median = 96 vs 68 days, p 0.0001; mean = 68 vs 60 days, p = 0.0044). ITR patients were 2-times more likely (p = 0.0110) to use other antifungals vs VOR patients. Controlling for treatment and key baseline variables, longer IFI prophylaxis was associated with fewer hospital days (p 0.0001) and less other antifungal use (p 0.0001). Patients who discontinued prophylaxis during the first 100 days incurred 10 more hospital days (p 0.0001) and 17 more other antifungal days (p 0.0001) compared to their counterparts. Eight more prophylaxis days were associated with ∼1 less hospital day and 3.6 less other antifungal days (p 0.0001). Key limitation: MRU data collection was limited to the first 100 days post-transplant, which may not fully capture the real-world utilization and outcomes.Patients' ability to tolerate and continue their antifungal prophylaxis after alloHCT is associated with less use of MRU such as other antifungals and hospital days. In the current resource-constrained healthcare environment, it is important to consider the potential economic impact of the tolerability of antifungal prophylaxis.
Published: 2013

37. US hospital database analysis of invasive aspergillosis in the chronic obstructive pulmonary disease non-traditional host

Author: Dipen Patel, Xin Gao, Mark S. Forshag, M. Tarallo, and Jennifer Stephens
Subjects: Male, medicine.medical_specialty, Multivariate analysis, Antifungal Agents, Databases, Factual, Antifungal drug, Aspergillosis, Pulmonary Disease, Chronic Obstructive, Internal medicine, medicine, Health Status Indicators, Humans, Intensive care medicine, Aged, Retrospective Studies, Voriconazole, Invasive Pulmonary Aspergillosis, COPD, business.industry, Health Policy, Case-control study, Retrospective cohort study, Length of Stay, medicine.disease, United States, respiratory tract diseases, Hospitalization, Case-Control Studies, Cohort, Multivariate Analysis, Female, business, medicine.drug
Abstract: Invasive aspergillosis (IA) is reported increasingly in non-traditional hosts, typically patients with chronic obstructive pulmonary disease (COPD). Objectives were to describe the excess burden of IA in COPD, including mortality, resource utilization, and costs, as well as to examine the impact of initial antifungal selection on clinical and economic outcomes.This retrospective cohort study used national data from 2005 to 2008, from the Premier Perspective hospital database. IA was identified using proxy ICD-9 codes based on published algorithms. The COPD + IA patient cohort was analyzed using descriptive statistics. Excess resource utilization was analyzed by matching cases (COPD + IA) and controls (COPD patients without aspergillosis) on demographic and clinical variables. Multivariate analyses were used to assess the impact of initial antifungal drug selection on outcomes in COPD + IA.In total, 475 COPD + IA patients were identified (mean age 69 years, 50% male, 76% Caucasian). COPD + IA cases had significantly higher costs, length of stay, intensive care unit (ICU) stay, and mortality compared to COPD controls (all p 0.01). On average, antifungal therapy was initiated on hospital day 6, with mean length of therapy 15 days, and one-third of patients were in the ICU when antifungal treatment was initiated. Most commonly used antifungals were voriconazole, fluconazole, and caspofungin. Patients receiving fluconazole as the initial antifungal, an agent inactive against moulds, had almost two times greater mortality (p = 0.016), two additional hospital days (p = 0.002), and 25% greater costs (p = 0.007), compared to patients receiving voriconazole first-line. Findings were consistent in sub-analyses including ICU patients.'Invasive' form of aspergillosis was identified using proxy ICD-9 codes based on published literature. Additional limitations stem from the study's non-randomized, retrospective design that is typical with any database analyses.COPD + IA patients had significantly higher mortality, resource utilization, and costs versus COPD controls. Treatment with an agent active against Aspergillus was associated with better survival and reduced economic burden, therefore this potential etiology of pneumonia should be considered when contemplating antifungal therapy in COPD patients.
Published: 2011

38. Fibroepithelioma of Pinkus: variant of basal cell carcinoma or trichoblastoma? Case report

Author: M, Tarallo, E, Cigna, P, Fino, F, Lo Torto, F, Corrias, and N, Scuderi
Subjects: Male, Skin Neoplasms, Neoplasms, Fibroepithelial, Humans, Aged, Neoplasms, Basal Cell
Abstract: Fibroepithelioma of Pinkus (FeP) is a rare tumor that most often affects women aged between 40 and 60 years. Clinically FeP presents as a soft, usually solitary, polypoid or papillomatous well circumscribed tumor of skin color. It is typically located to the trunk and extremities.A 75 year old male presented to our Department complaining for the presence of a lesion of the dorsal region. His medical history was free except for several basal cell carcinoma (BCC) surgically excised. Clinical examination revealed a pigmented lesion in the back. The lesion was surgically excised and histopathology showed of a fibroepithelioma of Pinkus.Currently, FeP is considered a rare variant of basal cell carcinoma, with characteristic histopathological features, although this view is somewhat controversial as some authors considered FeP to be a variant of trichoblastoma. The pathogenesis of FeP is still under investigation. It is thought that a mutation in the tumor suppressor gene TP53 might predispose to the development of FeP.Our case is interesting for two reasons. First, in our case FeP is pigmented. Moreover we present a case of Fep in a patient with a history of BCC, a finding that supports the classification of fibroepithelioma of Pinkus as a variant of basal cell carcinoma.
Published: 2011

39. All-sky search for periodic gravitational waves in LIGO S4 data

Author: B. Abbott, R. Abbott, R. Adhikari, J. Agresti, P. Ajith, B. Allen, R. Amin, S. B. Anderson, W. G. Anderson, M. Arain, M. Araya, H. Armandula, M. Ashley, S. Aston, P. Aufmuth, C. Aulbert, S. Babak, S. Ballmer, H. Bantilan, B. C. Barish, C. Barker, D. Barker, B. Barr, P. Barriga, M. A. Barton, K. Bayer, K. Belczynski, J. Betzwieser, P. T. Beyersdorf, B. Bhawal, I. A. Bilenko, G. Billingsley, R. Biswas, E. Black, K. Blackburn, L. Blackburn, D. Blair, B. Bland, J. Bogenstahl, L. Bogue, R. Bork, V. Boschi, S. Bose, P. R. Brady, V. B. Braginsky, J. E. Brau, M. Brinkmann, A. Brooks, D. A. Brown, A. Bullington, A. Bunkowski, A. Buonanno, O. Burmeister, D. Busby, R. L. Byer, L. Cadonati, G. Cagnoli, J. B. Camp, J. Cannizzo, K. Cannon, C. A. Cantley, J. Cao, L. Cardenas, M. M. Casey, G. Castaldi, C. Cepeda, E. Chalkey, P. Charlton, S. Chatterji, S. Chelkowski, Y. Chen, F. Chiadini, D. Chin, E. Chin, J. Chow, N. Christensen, J. Clark, P. Cochrane, T. Cokelaer, C. N. Colacino, R. Coldwell, R. Conte, D. Cook, T. Corbitt, D. Coward, D. Coyne, J. D. E. Creighton, T. D. Creighton, R. P. Croce, D. R. M. Crooks, A. M. Cruise, A. Cumming, J. Dalrymple, E. D’Ambrosio, K. Danzmann, G. Davies, D. DeBra, J. Degallaix, M. Degree, T. Demma, V. Dergachev, S. Desai, R. DeSalvo, S. Dhurandhar, M. Díaz, J. Dickson, A. Di Credico, G. Diederichs, A. Dietz, E. E. Doomes, R. W. P. Drever, J.-C. Dumas, R. J. Dupuis, J. G. Dwyer, P. Ehrens, E. Espinoza, T. Etzel, M. Evans, T. Evans, S. Fairhurst, Y. Fan, D. Fazi, M. M. Fejer, L. S. Finn, V. Fiumara, N. Fotopoulos, A. Franzen, K. Y. Franzen, A. Freise, R. Frey, T. Fricke, P. Fritschel, V. V. Frolov, M. Fyffe, V. Galdi, J. Garofoli, I. Gholami, J. A. Giaime, S. Giampanis, K. D. Giardina, K. Goda, E. Goetz, L. M. Goggin, G. González, S. Gossler, A. Grant, S. Gras, C. Gray, M. Gray, J. Greenhalgh, A. M. Gretarsson, R. Grosso, H. Grote, S. Grunewald, M. Guenther, R. Gustafson, B. Hage, D. Hammer, C. Hanna, J. Hanson, J. Harms, G. Harry, E. Harstad, T. Hayler, J. Heefner, I. S. Heng, A. Heptonstall, M. Heurs, M. Hewitson, S. Hild, E. Hirose, D. Hoak, D. Hosken, J. Hough, E. Howell, D. Hoyland, S. H. Huttner, D. Ingram, E. Innerhofer, M. Ito, Y. Itoh, A. Ivanov, D. Jackrel, B. Johnson, W. W. Johnson, D. I. Jones, G. Jones, R. Jones, L. Ju, P. Kalmus, V. Kalogera, D. Kasprzyk, E. Katsavounidis, K. Kawabe, S. Kawamura, F. Kawazoe, W. Kells, D. G. Keppel, F. Ya. Khalili, C. Kim, P. King, J. S. Kissel, S. Klimenko, K. Kokeyama, V. Kondrashov, R. K. Kopparapu, D. Kozak, B. Krishnan, P. Kwee, P. K. Lam, M. Landry, B. Lantz, A. Lazzarini, B. Lee, M. Lei, J. Leiner, V. Leonhardt, I. Leonor, K. Libbrecht, P. Lindquist, N. A. Lockerbie, M. Longo, M. Lormand, M. Lubinski, H. Lück, B. Machenschalk, M. MacInnis, M. Mageswaran, K. Mailand, M. Malec, V. Mandic, S. Marano, S. Márka, J. Markowitz, E. Maros, I. Martin, J. N. Marx, K. Mason, L. Matone, V. Matta, N. Mavalvala, R. McCarthy, D. E. McClelland, S. C. McGuire, M. McHugh, K. McKenzie, J. W. C. McNabb, S. McWilliams, T. Meier, A. Melissinos, G. Mendell, R. A. Mercer, S. Meshkov, E. Messaritaki, C. J. Messenger, D. Meyers, E. Mikhailov, S. Mitra, V. P. Mitrofanov, G. Mitselmakher, R. Mittleman, O. Miyakawa, S. Mohanty, G. Moreno, K. Mossavi, C. MowLowry, A. Moylan, D. Mudge, G. Mueller, S. Mukherjee, H. Müller-Ebhardt, J. Munch, P. Murray, E. Myers, J. Myers, T. Nash, G. Newton, A. Nishizawa, K. Numata, B. O’Reilly, R. O’Shaughnessy, D. J. Ottaway, H. Overmier, B. J. Owen, Y. Pan, M. A. Papa, V. Parameshwaraiah, P. Patel, M. Pedraza, S. Penn, V. Pierro, I. M. Pinto, M. Pitkin, H. Pletsch, M. V. Plissi, F. Postiglione, R. Prix, V. Quetschke, F. Raab, D. Rabeling, H. Radkins, R. Rahkola, N. Rainer, M. Rakhmanov, M. Ramsunder, K. Rawlins, S. Ray-Majumder, V. Re, H. Rehbein, S. Reid, D. H. Reitze, L. Ribichini, R. Riesen, K. Riles, B. Rivera, N. A. Robertson, C. Robinson, E. L. Robinson, S. Roddy, A. Rodriguez, A. M. Rogan, J. Rollins, J. D. Romano, J. Romie, R. Route, S. Rowan, A. Rüdiger, L. Ruet, P. Russell, K. Ryan, S. Sakata, M. Samidi, L. Sancho de la Jordana, V. Sandberg, V. Sannibale, S. Saraf, P. Sarin, B. S. Sathyaprakash, S. Sato, P. R. Saulson, R. Savage, P. Savov, S. Schediwy, R. Schilling, R. Schnabel, R. Schofield, B. F. Schutz, P. Schwinberg, S. M. Scott, A. C. Searle, B. Sears, F. Seifert, D. Sellers, A. S. Sengupta, P. Shawhan, D. H. Shoemaker, A. Sibley, J. A. Sidles, X. Siemens, D. Sigg, S. Sinha, A. M. Sintes, B. J. J. Slagmolen, J. Slutsky, J. R. Smith, M. R. Smith, K. Somiya, K. A. Strain, D. M. Strom, A. Stuver, T. Z. Summerscales, K.-X. Sun, M. Sung, P. J. Sutton, H. Takahashi, D. B. Tanner, M. Tarallo, R. Taylor, J. Thacker, K. A. Thorne, K. S. Thorne, A. Thüring, K. V. Tokmakov, C. Torres, C. Torrie, G. Traylor, M. Trias, W. Tyler, D. Ugolini, C. Ungarelli, K. Urbanek, H. Vahlbruch, M. Vallisneri, C. Van Den Broeck, M. Varvella, S. Vass, A. Vecchio, J. Veitch, P. Veitch, A. Villar, C. Vorvick, S. P. Vyachanin, S. J. Waldman, L. Wallace, H. Ward, R. Ward, K. Watts, D. Webber, A. Weidner, M. Weinert, A. Weinstein, R. Weiss, S. Wen, K. Wette, J. T. Whelan, D. M. Whitbeck, S. E. Whitcomb, B. F. Whiting, C. Wilkinson, P. A. Willems, L. Williams, B. Willke, I. Wilmut, W. Winkler, C. C. Wipf, S. Wise, A. G. Wiseman, G. Woan, D. Woods, R. Wooley, J. Worden, W. Wu, I. Yakushin, H. Yamamoto, Z. Yan, S. Yoshida, N. Yunes, M. Zanolin, J. Zhang, L. Zhang, C. Zhao, N. Zotov, M. Zucker, H. zur Mühlen, and J. Zweizig
Subjects: Physics, Nuclear and High Energy Physics, Gravitational-wave observatory, Einstein Telescope, 010308 nuclear & particles physics, Gravitational wave, General relativity, Astronomy, Astrophysics, 01 natural sciences, Gravitational-wave astronomy, LIGO, Neutron star, 0103 physical sciences, 010306 general physics, Gravitational redshift
Abstract: An error has been found in the computation of the C parameter defined in Eq. (44), which led to its overestimation by a factor 2(1/4). The correct values for C are 9.2, 9.7, and 9.3 for the multi-interferometer, H1 and L1 analyses, respectively. None of the upper limits presented in the article were affected.
Published: 2009

40. Publisher’s Note: Upper limits on gravitational wave emission from 78 radio pulsars [Phys. Rev. D76, 042001 (2007)]

Author: B. Abbott, R. Abbott, R. Adhikari, J. Agresti, P. Ajith, B. Allen, R. Amin, S. B. Anderson, W. G. Anderson, M. Arain, M. Araya, H. Armandula, M. Ashley, S. Aston, P. Aufmuth, C. Aulbert, S. Babak, S. Ballmer, H. Bantilan, B. C. Barish, C. Barker, D. Barker, B. Barr, P. Barriga, M. A. Barton, K. Bayer, K. Belczynski, J. Betzwieser, P. T. Beyersdorf, B. Bhawal, I. A. Bilenko, G. Billingsley, R. Biswas, E. Black, K. Blackburn, L. Blackburn, D. Blair, B. Bland, J. Bogenstahl, L. Bogue, R. Bork, V. Boschi, S. Bose, P. R. Brady, V. B. Braginsky, J. E. Brau, M. Brinkmann, A. Brooks, D. A. Brown, A. Bullington, A. Bunkowski, A. Buonanno, O. Burmeister, D. Busby, W. E. Butler, R. L. Byer, L. Cadonati, G. Cagnoli, J. B. Camp, J. Cannizzo, K. Cannon, C. A. Cantley, J. Cao, L. Cardenas, K. Carter, M. M. Casey, G. Castaldi, C. Cepeda, E. Chalkey, P. Charlton, S. Chatterji, S. Chelkowski, Y. Chen, F. Chiadini, D. Chin, E. Chin, J. Chow, N. Christensen, J. Clark, P. Cochrane, T. Cokelaer, C. N. Colacino, R. Coldwell, R. Conte, D. Cook, T. Corbitt, D. Coward, D. Coyne, J. D. E. Creighton, T. D. Creighton, R. P. Croce, D. R. M. Crooks, A. M. Cruise, A. Cumming, J. Dalrymple, E. D’Ambrosio, K. Danzmann, G. Davies, D. DeBra, J. Degallaix, M. Degree, T. Demma, V. Dergachev, S. Desai, R. DeSalvo, S. Dhurandhar, M. Diaz, J. Dickson, A. Di Credico, G. Diederichs, A. Dietz, E. E. Doomes, R. W. P. Drever, J.-C. Dumas, R. J. Dupuis, J. G. Dwyer, P. Ehrens, E. Espinoza, T. Etzel, M. Evans, T. Evans, S. Fairhurst, Y. Fan, D. Fazi, M. M. Fejer, L. S. Finn, V. Fiumara, N. Fotopoulos, A. Franzen, K. Y. Franzen, A. Freise, R. Frey, T. Fricke, P. Fritschel, V. V. Frolov, M. Fyffe, V. Galdi, K. S. Ganezer, J. Garofoli, I. Gholami, J. A. Giaime, S. Giampanis, K. D. Giardina, K. Goda, E. Goetz, L. Goggin, G. Gonzalez, S. Gossler, A. Grant, S. Gras, C. Gray, M. Gray, J. Greenhalgh, A. M. Gretarsson, R. Grosso, H. Grote, S. Grunewald, M. Guenther, R. Gustafson, B. Hage, D. Hammer, C. Hanna, J. Hanson, J. Harms, G. Harry, E. Harstad, T. Hayler, J. Heefner, I. S. Heng, A. Heptonstall, M. Heurs, M. Hewitson, S. Hild, E. Hirose, D. Hoak, D. Hosken, J. Hough, E. Howell, D. Hoyland, S. H. Huttner, D. Ingram, E. Innerhofer, M. Ito, Y. Itoh, A. Ivanov, D. Jackrel, B. Johnson, W. W. Johnson, D. I. Jones, G. Jones, R. Jones, L. Ju, P. Kalmus, V. Kalogera, D. Kasprzyk, E. Katsavounidis, K. Kawabe, S. Kawamura, F. Kawazoe, W. Kells, D. G. Keppel, F. Ya. Khalili, C. Kim, P. King, J. S. Kissel, S. Klimenko, K. Kokeyama, V. Kondrashov, R. K. Kopparapu, D. Kozak, B. Krishnan, P. Kwee, P. K. Lam, M. Landry, B. Lantz, A. Lazzarini, B. Lee, M. Lei, J. Leiner, V. Leonhardt, I. Leonor, K. Libbrecht, P. Lindquist, N. A. Lockerbie, M. Longo, M. Lormand, M. Lubinski, H. Luck, B. Machenschalk, M. MacInnis, M. Mageswaran, K. Mailand, M. Malec, V. Mandic, S. Marano, S. Marka, J. Markowitz, E. Maros, I. Martin, J. N. Marx, K. Mason, L. Matone, V. Matta, N. Mavalvala, R. McCarthy, D. E. McClelland, S. C. McGuire, M. McHugh, K. McKenzie, J. W. C. McNabb, S. McWilliams, T. Meier, A. Melissinos, G. Mendell, R. A. Mercer, S. Meshkov, E. Messaritaki, C. J. Messenger, D. Meyers, E. Mikhailov, S. Mitra, V. P. Mitrofanov, G. Mitselmakher, R. Mittleman, O. Miyakawa, S. Mohanty, G. Moreno, K. Mossavi, C. MowLowry, A. Moylan, D. Mudge, G. Mueller, S. Mukherjee, H. Muller-Ebhardt, J. Munch, P. Murray, E. Myers, J. Myers, T. Nash, G. Newton, A. Nishizawa, F. Nocera, K. Numata, B. O’Reilly, R. O’Shaughnessy, D. J. Ottaway, H. Overmier, B. J. Owen, Y. Pan, M. A. Papa, V. Parameshwaraiah, C. Parameshwaraiah, P. Patel, M. Pedraza, S. Penn, V. Pierro, I. M. Pinto, M. Pitkin, H. Pletsch, M. V. Plissi, F. Postiglione, R. Prix, V. Quetschke, F. Raab, D. Rabeling, H. Radkins, R. Rahkola, N. Rainer, M. Rakhmanov, K. Rawlins, S. Ray-Majumder, V. Re, T. Regimbau, H. Rehbein, S. Reid, D. H. Reitze, L. Ribichini, R. Riesen, K. Riles, B. Rivera, N. A. Robertson, C. Robinson, E. L. Robinson, S. Roddy, A. Rodriguez, A. M. Rogan, J. Rollins, J. D. Romano, J. Romie, R. Route, S. Rowan, A. Rudiger, L. Ruet, P. Russell, K. Ryan, S. Sakata, M. Samidi, L. Sancho de la Jordana, V. Sandberg, G. H. Sanders, V. Sannibale, S. Saraf, P. Sarin, B. S. Sathyaprakash, S. Sato, P. R. Saulson, R. Savage, P. Savov, A. Sazonov, S. Schediwy, R. Schilling, R. Schnabel, R. Schofield, B. F. Schutz, P. Schwinberg, S. M. Scott, A. C. Searle, B. Sears, F. Seifert, D. Sellers, A. S. Sengupta, P. Shawhan, D. H. Shoemaker, A. Sibley, J. A. Sidles, X. Siemens, D. Sigg, S. Sinha, A. M. Sintes, B. J. J. Slagmolen, J. Slutsky, J. R. Smith, M. R. Smith, K. Somiya, K. A. Strain, D. M. Strom, A. Stuver, T. Z. Summerscales, K.-X. Sun, M. Sung, P. J. Sutton, H. Takahashi, D. B. Tanner, M. Tarallo, R. Taylor, J. Thacker, K. A. Thorne, K. S. Thorne, A. Thuring, K. V. Tokmakov, C. Torres, C. Torrie, G. Traylor, M. Trias, W. Tyler, D. Ugolini, C. Ungarelli, K. Urbanek, H. Vahlbruch, M. Vallisneri, C. Van Den Broeck, M. van Putten, M. Varvella, S. Vass, A. Vecchio, J. Veitch, P. Veitch, A. Villar, C. Vorvick, S. P. Vyachanin, S. J. Waldman, L. Wallace, H. Ward, R. Ward, K. Watts, D. Webber, A. Weidner, M. Weinert, A. Weinstein, R. Weiss, S. Wen, K. Wette, J. T. Whelan, D. M. Whitbeck, S. E. Whitcomb, B. F. Whiting, S. Wiley, C. Wilkinson, P. A. Willems, L. Williams, B. Willke, I. Wilmut, W. Winkler, C. C. Wipf, S. Wise, A. G. Wiseman, G. Woan, D. Woods, R. Wooley, J. Worden, W. Wu, I. Yakushin, H. Yamamoto, Z. Yan, S. Yoshida, N. Yunes, M. Zanolin, J. Zhang, L. Zhang, C. Zhao, N. Zotov, M. Zucker, H. zur Muhlen, J. Zweizig, M. Kramer, and A. G. Lyne
Subjects: Gravitation, Physics, Nuclear and High Energy Physics, Gravitational-wave observatory, Gravitational wave, Speed of gravity, Astronomy, Astrophysics, Cosmology, LIGO, Gravitational energy, Gravitational redshift
Abstract: This paper was published online on 3 August 2007 with a formatting error in the fifty-first affiliation in the author list.The affiliation should read as ‘‘University of Western Australia, Crawley, WA 6009, Australia.’’ The affiliation has beencorrected as of 4 March 2008. The affiliation is incorrect in the printed version of the journal.
Published: 2008
Full Text: View/download PDF

41. Upper limit map of a background of gravitational waves

Author: B. Abbott, R. Abbott, R. Adhikari, J. Agresti, P. Ajith, B. Allen, R. Amin, S. B. Anderson, W. G. Anderson, M. Arain, M. Araya, H. Armandula, M. Ashley, S. Aston, P. Aufmuth, C. Aulbert, S. Babak, S. Ballmer, H. Bantilan, B. C. Barish, C. Barker, D. Barker, B. Barr, P. Barriga, M. A. Barton, K. Bayer, K. Belczynski, J. Betzwieser, P. T. Beyersdorf, B. Bhawal, I. A. Bilenko, G. Billingsley, R. Biswas, E. Black, K. Blackburn, L. Blackburn, D. Blair, B. Bland, J. Bogenstahl, L. Bogue, R. Bork, V. Boschi, S. Bose, P. R. Brady, V. B. Braginsky, J. E. Brau, M. Brinkmann, A. Brooks, D. A. Brown, A. Bullington, A. Bunkowski, A. Buonanno, O. Burmeister, D. Busby, R. L. Byer, L. Cadonati, G. Cagnoli, J. B. Camp, J. Cannizzo, K. Cannon, C. A. Cantley, J. Cao, L. Cardenas, M. M. Casey, G. Castaldi, C. Cepeda, E. Chalkey, P. Charlton, S. Chatterji, S. Chelkowski, Y. Chen, F. Chiadini, D. Chin, E. Chin, J. Chow, N. Christensen, J. Clark, P. Cochrane, T. Cokelaer, C. N. Colacino, R. Coldwell, R. Conte, D. Cook, T. Corbitt, D. Coward, D. Coyne, J. D. E. Creighton, T. D. Creighton, R. P. Croce, D. R. M. Crooks, A. M. Cruise, A. Cumming, J. Dalrymple, E. D’Ambrosio, K. Danzmann, G. Davies, D. DeBra, J. Degallaix, M. Degree, T. Demma, V. Dergachev, S. Desai, R. DeSalvo, S. Dhurandhar, M. Diaz, J. Dickson, A. Di Credico, G. Diederichs, A. Dietz, E. E. Doomes, R. W. P. Drever, J.-C. Dumas, R. J. Dupuis, J. G. Dwyer, P. Ehrens, E. Espinoza, T. Etzel, M. Evans, T. Evans, S. Fairhurst, Y. Fan, D. Fazi, M. M. Fejer, L. S. Finn, V. Fiumara, N. Fotopoulos, A. Franzen, K. Y. Franzen, A. Freise, R. Frey, T. Fricke, P. Fritschel, V. V. Frolov, M. Fyffe, V. Galdi, J. Garofoli, I. Gholami, J. A. Giaime, S. Giampanis, K. D. Giardina, K. Goda, E. Goetz, L. M. Goggin, G. Gonzalez, S. Gossler, A. Grant, S. Gras, C. Gray, M. Gray, J. Greenhalgh, A. M. Gretarsson, R. Grosso, H. Grote, S. Grunewald, M. Guenther, R. Gustafson, B. Hage, D. Hammer, C. Hanna, J. Hanson, J. Harms, G. Harry, E. Harstad, T. Hayler, J. Heefner, I. S. Heng, A. Heptonstall, M. Heurs, M. Hewitson, S. Hild, E. Hirose, D. Hoak, D. Hosken, J. Hough, E. Howell, D. Hoyland, S. H. Huttner, D. Ingram, E. Innerhofer, M. Ito, Y. Itoh, A. Ivanov, D. Jackrel, B. Johnson, W. W. Johnson, D. I. Jones, G. Jones, R. Jones, L. Ju, P. Kalmus, V. Kalogera, D. Kasprzyk, E. Katsavounidis, K. Kawabe, S. Kawamura, F. Kawazoe, W. Kells, D. G. Keppel, F. Ya. Khalili, C. Kim, P. King, J. S. Kissel, S. Klimenko, K. Kokeyama, V. Kondrashov, R. K. Kopparapu, D. Kozak, B. Krishnan, P. Kwee, P. K. Lam, M. Landry, B. Lantz, A. Lazzarini, B. Lee, M. Lei, J. Leiner, V. Leonhardt, I. Leonor, K. Libbrecht, P. Lindquist, N. A. Lockerbie, M. Longo, M. Lormand, M. Lubinski, H. Luck, B. Machenschalk, M. MacInnis, M. Mageswaran, K. Mailand, M. Malec, V. Mandic, S. Marano, S. Marka, J. Markowitz, E. Maros, I. Martin, J. N. Marx, K. Mason, L. Matone, V. Matta, N. Mavalvala, R. McCarthy, D. E. McClelland, S. C. McGuire, M. McHugh, K. McKenzie, J. W. C. McNabb, S. McWilliams, T. Meier, A. Melissinos, G. Mendell, R. A. Mercer, S. Meshkov, E. Messaritaki, C. J. Messenger, D. Meyers, E. Mikhailov, S. Mitra, V. P. Mitrofanov, G. Mitselmakher, R. Mittleman, O. Miyakawa, S. Mohanty, G. Moreno, K. Mossavi, C. MowLowry, A. Moylan, D. Mudge, G. Mueller, S. Mukherjee, H. Muller-Ebhardt, J. Munch, P. Murray, E. Myers, J. Myers, G. Newton, A. Nishizawa, K. Numata, B. O’Reilly, R. O’Shaughnessy, D. J. Ottaway, H. Overmier, B. J. Owen, Y. Pan, M. A. Papa, V. Parameshwaraiah, P. Patel, M. Pedraza, S. Penn, V. Pierro, I. M. Pinto, M. Pitkin, H. Pletsch, M. V. Plissi, F. Postiglione, R. Prix, V. Quetschke, F. Raab, D. Rabeling, H. Radkins, R. Rahkola, N. Rainer, M. Rakhmanov, K. Rawlins, S. Ray-Majumder, V. Re, H. Rehbein, S. Reid, D. H. Reitze, L. Ribichini, R. Riesen, K. Riles, B. Rivera, N. A. Robertson, C. Robinson, E. L. Robinson, S. Roddy, A. Rodriguez, A. M. Rogan, J. Rollins, J. D. Romano, J. Romie, R. Route, S. Rowan, A. Rudiger, L. Ruet, P. Russell, K. Ryan, S. Sakata, M. Samidi, L. Sancho de la Jordana, V. Sandberg, V. Sannibale, S. Saraf, P. Sarin, B. S. Sathyaprakash, S. Sato, P. R. Saulson, R. Savage, P. Savov, S. Schediwy, R. Schilling, R. Schnabel, R. Schofield, B. F. Schutz, P. Schwinberg, S. M. Scott, A. C. Searle, B. Sears, F. Seifert, D. Sellers, A. S. Sengupta, P. Shawhan, D. H. Shoemaker, A. Sibley, J. A. Sidles, X. Siemens, D. Sigg, S. Sinha, A. M. Sintes, B. J. J. Slagmolen, J. Slutsky, J. R. Smith, M. R. Smith, K. Somiya, K. A. Strain, D. M. Strom, A. Stuver, T. Z. Summerscales, K.-X. Sun, M. Sung, P. J. Sutton, H. Takahashi, D. B. Tanner, M. Tarallo, R. Taylor, J. Thacker, K. A. Thorne, K. S. Thorne, A. Thuring, K. V. Tokmakov, C. Torres, C. Torrie, G. Traylor, M. Trias, W. Tyler, D. Ugolini, C. Ungarelli, K. Urbanek, H. Vahlbruch, M. Vallisneri, C. Van Den Broeck, M. Varvella, S. Vass, A. Vecchio, J. Veitch, P. Veitch, A. Villar, C. Vorvick, S. P. Vyachanin, S. J. Waldman, L. Wallace, H. Ward, R. Ward, K. Watts, D. Webber, A. Weidner, M. Weinert, A. Weinstein, R. Weiss, S. Wen, K. Wette, J. T. Whelan, D. M. Whitbeck, S. E. Whitcomb, B. F. Whiting, C. Wilkinson, P. A. Willems, L. Williams, B. Willke, I. Wilmut, W. Winkler, C. C. Wipf, S. Wise, A. G. Wiseman, G. Woan, D. Woods, R. Wooley, J. Worden, W. Wu, I. Yakushin, H. Yamamoto, Z. Yan, S. Yoshida, N. Yunes, M. Zanolin, J. Zhang, L. Zhang, C. Zhao, N. Zotov, M. Zucker, H. zur Muhlen, J. Zweizig, and The LIGO Scientific Collaboration
Subjects: Gravitational constant, Physics, Nuclear and High Energy Physics, Theoretical physics, Gravitational field, Gravitational wave, General relativity, Speed of gravity, Gravity Probe A, Astrophysics, Cosmology, Gravitational redshift
Abstract: This paper was published online on 29 October 2007 with a formatting error in the fiftieth affiliation in the author list. The affiliation should read as ‘‘University of Western Australia, Crawley, WA 6009, Australia.’’ The affiliation has been corrected as of 4 March 2008. The affiliation is incorrect in the printed version of the journal.
Published: 2008

42. First cross-correlation analysis of interferometric and resonant-bar gravitational-wave data for stochastic backgrounds

Author: B. Abbott, R. Abbott, R. Adhikari, J. Agresti, P. Ajith, B. Allen, R. Amin, S. B. Anderson, W. G. Anderson, M. Arain, M. Araya, H. Armandula, M. Ashley, S. Aston, P. Aufmuth, C. Aulbert, S. Babak, S. Ballmer, H. Bantilan, B. C. Barish, C. Barker, D. Barker, B. Barr, P. Barriga, M. A. Barton, K. Bayer, K. Belczynski, J. Betzwieser, P. T. Beyersdorf, B. Bhawal, I. A. Bilenko, G. Billingsley, R. Biswas, E. Black, K. Blackburn, L. Blackburn, D. Blair, B. Bland, J. Bogenstahl, L. Bogue, R. Bork, V. Boschi, S. Bose, P. R. Brady, V. B. Braginsky, J. E. Brau, M. Brinkmann, A. Brooks, D. A. Brown, A. Bullington, A. Bunkowski, A. Buonanno, M. Burgamy, O. Burmeister, D. Busby, R. L. Byer, L. Cadonati, G. Cagnoli, J. B. Camp, J. Cannizzo, K. Cannon, C. A. Cantley, J. Cao, L. Cardenas, M. M. Casey, G. Castaldi, C. Cepeda, E. Chalkey, P. Charlton, S. Chatterji, S. Chelkowski, Y. Chen, F. Chiadini, D. Chin, E. Chin, J. Chow, N. Christensen, J. Clark, P. Cochrane, T. Cokelaer, C. N. Colacino, R. Coldwell, R. Conte, D. Cook, T. Corbitt, D. Coward, D. Coyne, J. D. E. Creighton, T. D. Creighton, R. P. Croce, D. R. M. Crooks, A. M. Cruise, A. Cumming, J. Dalrymple, E. D’Ambrosio, K. Danzmann, G. Davies, D. DeBra, J. Degallaix, M. Degree, T. Demma, V. Dergachev, S. Desai, R. DeSalvo, S. Dhurandhar, M. Diaz, J. Dickson, A. Di Credico, G. Diederichs, A. Dietz, E. E. Doomes, R. W. P. Drever, J.-C. Dumas, R. J. Dupuis, J. G. Dwyer, P. Ehrens, E. Espinoza, T. Etzel, M. Evans, T. Evans, S. Fairhurst, Y. Fan, D. Fazi, M. M. Fejer, L. S. Finn, V. Fiumara, N. Fotopoulos, A. Franzen, K. Y. Franzen, A. Freise, R. Frey, T. Fricke, P. Fritschel, V. V. Frolov, M. Fyffe, V. Galdi, J. Garofoli, I. Gholami, J. A. Giaime, S. Giampanis, K. D. Giardina, K. Goda, E. Goetz, L. Goggin, G. Gonzalez, S. Gossler, A. Grant, S. Gras, C. Gray, M. Gray, J. Greenhalgh, A. M. Gretarsson, R. Grosso, H. Grote, S. Grunewald, M. Guenther, R. Gustafson, B. Hage, W. O. Hamilton, D. Hammer, C. Hanna, J. Hanson, J. Harms, G. Harry, E. Harstad, T. Hayler, J. Heefner, I. S. Heng, A. Heptonstall, M. Heurs, M. Hewitson, S. Hild, E. Hirose, D. Hoak, D. Hosken, J. Hough, E. Howell, D. Hoyland, S. H. Huttner, D. Ingram, E. Innerhofer, M. Ito, Y. Itoh, A. Ivanov, D. Jackrel, B. Johnson, W. W. Johnson, D. I. Jones, G. Jones, R. Jones, L. Ju, P. Kalmus, V. Kalogera, D. Kasprzyk, E. Katsavounidis, K. Kawabe, S. Kawamura, F. Kawazoe, W. Kells, D. G. Keppel, F. Ya. Khalili, C. Kim, P. King, J. S. Kissel, S. Klimenko, K. Kokeyama, V. Kondrashov, R. K. Kopparapu, D. Kozak, B. Krishnan, P. Kwee, P. K. Lam, M. Landry, B. Lantz, A. Lazzarini, B. Lee, M. Lei, J. Leiner, V. Leonhardt, I. Leonor, K. Libbrecht, P. Lindquist, N. A. Lockerbie, M. Longo, M. Lormand, M. Lubinski, H. Luck, B. Machenschalk, M. MacInnis, M. Mageswaran, K. Mailand, M. Malec, V. Mandic, S. Marano, S. Marka, J. Markowitz, E. Maros, I. Martin, J. N. Marx, K. Mason, L. Matone, V. Matta, N. Mavalvala, R. McCarthy, B. J. McCaulley, D. E. McClelland, S. C. McGuire, M. McHugh, K. McKenzie, J. W. C. McNabb, S. McWilliams, T. Meier, A. Melissinos, G. Mendell, R. A. Mercer, S. Meshkov, E. Messaritaki, C. J. Messenger, D. Meyers, E. Mikhailov, P. Miller, S. Mitra, V. P. Mitrofanov, G. Mitselmakher, R. Mittleman, O. Miyakawa, S. Mohanty, V. Moody, G. Moreno, K. Mossavi, C. MowLowry, A. Moylan, D. Mudge, G. Mueller, S. Mukherjee, H. Muller-Ebhardt, J. Munch, P. Murray, E. Myers, J. Myers, T. Nash, G. Newton, A. Nishizawa, K. Numata, B. O’Reilly, R. O’Shaughnessy, D. J. Ottaway, H. Overmier, B. J. Owen, H.-J. Paik, Y. Pan, M. A. Papa, V. Parameshwaraiah, P. Patel, M. Pedraza, S. Penn, V. Pierro, I. M. Pinto, M. Pitkin, H. Pletsch, M. V. Plissi, F. Postiglione, R. Prix, V. Quetschke, F. Raab, D. Rabeling, H. Radkins, R. Rahkola, N. Rainer, M. Rakhmanov, M. Ramsuder, K. Rawlins, S. Ray-Majumder, V. Re, H. Rehbein, S. Reid, D. H. Reitze, L. Ribichini, R. Riesen, K. Riles, B. Rivera, N. A. Robertson, C. Robinson, E. L. Robinson, S. Roddy, A. Rodriguez, A. M. Rogan, J. Rollins, J. D. Romano, J. Romie, R. Route, S. Rowan, A. Rudiger, L. Ruet, P. Russell, K. Ryan, S. Sakata, M. Samidi, L. Sancho de la Jordana, V. Sandberg, V. Sannibale, S. Saraf, P. Sarin, B. S. Sathyaprakash, S. Sato, P. R. Saulson, R. Savage, P. Savov, S. Schediwy, R. Schilling, R. Schnabel, R. Schofield, B. F. Schutz, P. Schwinberg, S. M. Scott, A. C. Searle, B. Sears, F. Seifert, D. Sellers, A. S. Sengupta, P. Shawhan, D. H. Shoemaker, A. Sibley, J. A. Sidles, X. Siemens, D. Sigg, S. Sinha, A. M. Sintes, B. J. J. Slagmolen, J. Slutsky, J. R. Smith, M. R. Smith, K. Somiya, K. A. Strain, D. M. Strom, A. Stuver, T. Z. Summerscales, K.-X. Sun, M. Sung, P. J. Sutton, H. Takahashi, D. B. Tanner, M. Tarallo, R. Taylor, J. Thacker, K. A. Thorne, K. S. Thorne, A. Thuring, K. V. Tokmakov, C. Torres, C. Torrie, G. Traylor, M. Trias, W. Tyler, D. Ugolini, C. Ungarelli, K. Urbanek, H. Vahlbruch, M. Vallisneri, C. Van Den Broeck, M. Varvella, S. Vass, A. Vecchio, J. Veitch, P. Veitch, A. Villar, C. Vorvick, S. P. Vyachanin, S. J. Waldman, L. Wallace, H. Ward, R. Ward, K. Watts, J. Weaver, D. Webber, A. Weber, A. Weidner, M. Weinert, A. Weinstein, R. Weiss, S. Wen, K. Wette, J. T. Whelan, D. M. Whitbeck, S. E. Whitcomb, B. F. Whiting, C. Wilkinson, P. A. Willems, L. Williams, B. Willke, I. Wilmut, W. Winkler, C. C. Wipf, S. Wise, A. G. Wiseman, G. Woan, D. Woods, R. Wooley, J. Worden, W. Wu, I. Yakushin, H. Yamamoto, Z. Yan, S. Yoshida, N. Yunes, M. Zanolin, J. Zhang, L. Zhang, P. Zhang, C. Zhao, N. Zotov, M. Zucker, H. zur Muhlen, J. Zweizig, The LIGO Scientific Collaboration, and ALLEGRO Collaboration
Subjects: Gravitation, Physics, Nuclear and High Energy Physics, Theoretical physics, Interferometry, Bar (music), Gravitational wave, Cross correlation analysis, LIGO, Cosmology, LIGO Scientific Collaboration
Abstract: This paper was published online on 9 July 2007 with a formatting error in the fiftieth affiliation in the author list. The affiliation should read as ‘‘University of Western Australia, Crawley, WA 6009, Australia.’’ The affiliation has been corrected as of 4 March 2008. The affiliation is incorrect in the printed version of the journal.
Published: 2008

43. Publisher’s Note: First cross-correlation analysis of interferometric and resonant-bar gravitational-wave data for stochastic backgrounds [Phys. Rev. DPRVDAQ0556-282176, 022001 (2007)]

Author: B Abbott, R. Abbott, R. Adhikari, J. Agresti, P. Ajith, B. Allen, R. Amin, S. B. Anderson, W. G. Anderson, M. Arain, M. Araya, H. Armandula, M. Ashley, S. Aston, P. Aufmuth, C. Aulbert, S. Babak, S. Ballmer, H. Bantilan, B. C. Barish, C. Barker, D. Barker, B. Barr, P. Barriga, M. A. Barton, K. Bayer, K. Belczynski, J. Betzwieser, P. T. Beyersdorf, B. Bhawal, I. A. Bilenko, G. Billingsley, R. Biswas, E. Black, K. Blackburn, L. Blackburn, D. Blair, B. Bland, J. Bogenstahl, L. Bogue, R. Bork, V. Boschi, S. Bose, P. R. Brady, V. B. Braginsky, J. E. Brau, M. Brinkmann, A. Brooks, D. A. Brown, A. Bullington, A. Bunkowski, A. Buonanno, M. Burgamy, O. Burmeister, D. Busby, R. L. Byer, L. Cadonati, G. Cagnoli, J. B. Camp, J. Cannizzo, K. Cannon, C. A. Cantley, J. Cao, L. Cardenas, M. M. Casey, G. Castaldi, C. Cepeda, E. Chalkey, P. Charlton, S. Chatterji, S. Chelkowski, Y. Chen, F. Chiadini, D. Chin, E. Chin, J. Chow, N. Christensen, J. Clark, P. Cochrane, T. Cokelaer, C. N. Colacino, R. Coldwell, R. Conte, D. Cook, T. Corbitt, D. Coward, D. Coyne, J. D. E. Creighton, T. D. Creighton, R. P. Croce, D. R. M. Crooks, A. M. Cruise, A. Cumming, J. Dalrymple, E. D’Ambrosio, K. Danzmann, G. Davies, D. DeBra, J. Degallaix, M. Degree, T. Demma, V. Dergachev, S. Desai, R. DeSalvo, S. Dhurandhar, M. Diaz, J. Dickson, A. Di Credico, G. Diederichs, A. Dietz, E. E. Doomes, R. W. P. Drever, J.-C. Dumas, R. J. Dupuis, J. G. Dwyer, P. Ehrens, E. Espinoza, T. Etzel, M. Evans, T. Evans, S. Fairhurst, Y. Fan, D. Fazi, M. M. Fejer, L. S. Finn, V. Fiumara, N. Fotopoulos, A. Franzen, K. Y. Franzen, A. Freise, R. Frey, T. Fricke, P. Fritschel, V. V. Frolov, M. Fyffe, V. Galdi, J. Garofoli, I. Gholami, J. A. Giaime, S. Giampanis, K. D. Giardina, K. Goda, E. Goetz, L. Goggin, G. Gonzalez, S. Gossler, A. Grant, S. Gras, C. Gray, M. Gray, J. Greenhalgh, A. M. Gretarsson, R. Grosso, H. Grote, S. Grunewald, M. Guenther, R. Gustafson, B. Hage, W. O. Hamilton, D. Hammer, C. Hanna, J. Hanson, J. Harms, G. Harry, E. Harstad, T. Hayler, J. Heefner, I. S. Heng, A. Heptonstall, M. Heurs, M. Hewitson, S. Hild, E. Hirose, D. Hoak, D. Hosken, J. Hough, E. Howell, D. Hoyland, S. H. Huttner, D. Ingram, E. Innerhofer, M. Ito, Y. Itoh, A. Ivanov, D. Jackrel, B. Johnson, W. W. Johnson, D. I. Jones, G. Jones, R. Jones, L. Ju, P. Kalmus, V. Kalogera, D. Kasprzyk, E. Katsavounidis, K. Kawabe, S. Kawamura, F. Kawazoe, W. Kells, D. G. Keppel, F. Ya. Khalili, C. Kim, P. King, J. S. Kissel, S. Klimenko, K. Kokeyama, V. Kondrashov, R. K. Kopparapu, D. Kozak, B. Krishnan, P. Kwee, P. K. Lam, M. Landry, B. Lantz, A. Lazzarini, B. Lee, M. Lei, J. Leiner, V. Leonhardt, I. Leonor, K. Libbrecht, P. Lindquist, N. A. Lockerbie, M. Longo, M. Lormand, M. Lubinski, H. Luck, B. Machenschalk, M. MacInnis, M. Mageswaran, K. Mailand, M. Malec, V. Mandic, S. Marano, S. Marka, J. Markowitz, E. Maros, I. Martin, J. N. Marx, K. Mason, L. Matone, V. Matta, N. Mavalvala, R. McCarthy, B. J. McCaulley, D. E. McClelland, S. C. McGuire, M. McHugh, K. McKenzie, J. W. C. McNabb, S. McWilliams, T. Meier, A. Melissinos, G. Mendell, R. A. Mercer, S. Meshkov, E. Messaritaki, C. J. Messenger, D. Meyers, E. Mikhailov, P. Miller, S. Mitra, V. P. Mitrofanov, G. Mitselmakher, R. Mittleman, O. Miyakawa, S. Mohanty, V. Moody, G. Moreno, K. Mossavi, C. MowLowry, A. Moylan, D. Mudge, G. Mueller, S. Mukherjee, H. Muller-Ebhardt, J. Munch, P. Murray, E. Myers, J. Myers, T. Nash, G. Newton, A. Nishizawa, K. Numata, B. O’Reilly, R. O’Shaughnessy, D. J. Ottaway, H. Overmier, B. J. Owen, H.-J. Paik, Y. Pan, M. A. Papa, V. Parameshwaraiah, P. Patel, M. Pedraza, S. Penn, V. Pierro, I. M. Pinto, M. Pitkin, H. Pletsch, M. V. Plissi, F. Postiglione, R. Prix, V. Quetschke, F. Raab, D. Rabeling, H. Radkins, R. Rahkola, N. Rainer, M. Rakhmanov, M. Ramsuder, K. Rawlins, S. Ray-Majumder, V. Re, H. Rehbein, S. Reid, D. H. Reitze, L. Ribichini, R. Riesen, K. Riles, B. Rivera, N. A. Robertson, C. Robinson, E. L. Robinson, S. Roddy, A. Rodriguez, A. M. Rogan, J. Rollins, J. D. Romano, J. Romie, R. Route, S. Rowan, A. Rudiger, L. Ruet, P. Russell, K. Ryan, S. Sakata, M. Samidi, L. Sancho de la Jordana, V. Sandberg, V. Sannibale, S. Saraf, P. Sarin, B. S. Sathyaprakash, S. Sato, P. R. Saulson, R. Savage, P. Savov, S. Schediwy, R. Schilling, R. Schnabel, R. Schofield, B. F. Schutz, P. Schwinberg, S. M. Scott, A. C. Searle, B. Sears, F. Seifert, D. Sellers, A. S. Sengupta, P. Shawhan, D. H. Shoemaker, A. Sibley, J. A. Sidles, X. Siemens, D. Sigg, S. Sinha, A. M. Sintes, B. J. J. Slagmolen, J. Slutsky, J. R. Smith, M. R. Smith, K. Somiya, K. A. Strain, D. M. Strom, A. Stuver, T. Z. Summerscales, K.-X. Sun, M. Sung, P. J. Sutton, H. Takahashi, D. B. Tanner, M. Tarallo, R. Taylor, J. Thacker, K. A. Thorne, K. S. Thorne, A. Thuring, K. V. Tokmakov, C. Torres, C. Torrie, G. Traylor, M. Trias, W. Tyler, D. Ugolini, C. Ungarelli, K. Urbanek, H. Vahlbruch, M. Vallisneri, C. Van Den Broeck, M. Varvella, S. Vass, A. Vecchio, J. Veitch, P. Veitch, A. Villar, C. Vorvick, S. P. Vyachanin, S. J. Waldman, L. Wallace, H. Ward, R. Ward, K. Watts, J. Weaver, D. Webber, A. Weber, A. Weidner, M. Weinert, A. Weinstein, R. Weiss, S. Wen, K. Wette, J. T. Whelan, D. M. Whitbeck, S. E. Whitcomb, B. F. Whiting, C. Wilkinson, P. A. Willems, L. Williams, B. Willke, I. Wilmut, W. Winkler, C. C. Wipf, S. Wise, A. G. Wiseman, G. Woan, D. Woods, R. Wooley, J. Worden, W. Wu, I. Yakushin, H. Yamamoto, Z. Yan, S. Yoshida, N. Yunes, M. Zanolin, J. Zhang, L. Zhang, P. Zhang, C. Zhao, N. Zotov, M. Zucker, H. zur Muhlen, and J. Zweizig
Subjects: Physics, Nuclear and High Energy Physics, Cross correlation analysis, Humanities
Abstract: B. Abbott, R. Abbott, R. Adhikari, J. Agresti, P. Ajith, B. Allen, R. Amin, S. B. Anderson, W. G. Anderson, M. Arain, M. Araya, H. Armandula, M. Ashley, S. Aston, P. Aufmuth, C. Aulbert, S. Babak, S. Ballmer, H. Bantilan, B. C. Barish, C. Barker, D. Barker, B. Barr, P. Barriga, M. A. Barton, K. Bayer, K. Belczynski, J. Betzwieser, P. T. Beyersdorf, B. Bhawal, I. A. Bilenko, G. Billingsley, R. Biswas, E. Black, K. Blackburn, L. Blackburn, D. Blair, B. Bland, J. Bogenstahl, L. Bogue, R. Bork, V. Boschi, S. Bose, P. R. Brady, V. B. Braginsky, J. E. Brau, M. Brinkmann, A. Brooks, D. A. Brown, A. Bullington, A. Bunkowski, A. Buonanno, M. Burgamy, O. Burmeister, D. Busby, R. L. Byer, L. Cadonati, G. Cagnoli, J. B. Camp, J. Cannizzo, K. Cannon, C. A. Cantley, J. Cao, L. Cardenas, M. M. Casey, G. Castaldi, C. Cepeda, E. Chalkey, P. Charlton, S. Chatterji, S. Chelkowski, Y. Chen, F. Chiadini, D. Chin, E. Chin, J. Chow, N. Christensen, J. Clark, P. Cochrane, T. Cokelaer, C. N. Colacino, R. Coldwell, R. Conte, D. Cook, T. Corbitt, D. Coward, D. Coyne, J. D. E. Creighton, T. D. Creighton, R. P. Croce, D. R. M. Crooks, A. M. Cruise, A. Cumming, J. Dalrymple, E. D’Ambrosio, K. Danzmann, G. Davies, D. DeBra, J. Degallaix, M. Degree, T. Demma, V. Dergachev, S. Desai, R. DeSalvo, S. Dhurandhar, M. Diaz, J. Dickson, A. Di Credico, G. Diederichs, A. Dietz, E. E. Doomes, R. W. P. Drever, J.-C. Dumas, R. J. Dupuis, J. G. Dwyer, P. Ehrens, E. Espinoza, T. Etzel, M. Evans, T. Evans, S. Fairhurst, Y. Fan, D. Fazi, M. M. Fejer, L. S. Finn, V. Fiumara, N. Fotopoulos, A. Franzen, K. Y. Franzen, A. Freise, R. Frey, T. Fricke, P. Fritschel, V. V. Frolov, M. Fyffe, V. Galdi, J. Garofoli, I. Gholami, J. A. Giaime, S. Giampanis, K. D. Giardina, K. Goda, E. Goetz, L. Goggin, G. Gonzalez, S. Gossler, A. Grant, S. Gras, C. Gray, M. Gray, J. Greenhalgh, A. M. Gretarsson, R. Grosso, H. Grote, S. Grunewald, M. Guenther, R. Gustafson, B. Hage, W. O. Hamilton, D. Hammer, C. Hanna, J. Hanson, J. Harms, G. Harry, E. Harstad, T. Hayler, J. Heefner, I. S. Heng, A. Heptonstall, M. Heurs, M. Hewitson, S. Hild, E. Hirose, D. Hoak, D. Hosken, J. Hough, E. Howell, D. Hoyland, S. H. Huttner, D. Ingram, E. Innerhofer, M. Ito, Y. Itoh, A. Ivanov, D. Jackrel, B. Johnson, W. W. Johnson, D. I. Jones, G. Jones, R. Jones, L. Ju, P. Kalmus, V. Kalogera, D. Kasprzyk, E. Katsavounidis, K. Kawabe, S. Kawamura, F. Kawazoe, W. Kells, D. G. Keppel, F. Ya. Khalili, C. Kim, P. King, J. S. Kissel, S. Klimenko, K. Kokeyama, V. Kondrashov, R. K. Kopparapu, D. Kozak, B. Krishnan, P. Kwee, P. K. Lam, M. Landry, B. Lantz, A. Lazzarini, B. Lee, M. Lei, J. Leiner, V. Leonhardt, I. Leonor, K. Libbrecht, P. Lindquist, N. A. Lockerbie, M. Longo, M. Lormand, M. Lubinski, H. Luck, B. Machenschalk, M. MacInnis, M. Mageswaran, K. Mailand, M. Malec, V. Mandic, S. Marano, S. Marka, J. Markowitz, E. Maros, I. Martin, J. N. Marx, K. Mason, L. Matone, V. Matta, N. Mavalvala, R. McCarthy, B. J. McCaulley, D. E. McClelland, S. C. McGuire, M. McHugh, K. McKenzie, J. W. C. McNabb, S. McWilliams, T. Meier, A. Melissinos, G. Mendell, R. A. Mercer, S. Meshkov, E. Messaritaki, C. J. Messenger, D. Meyers, E. Mikhailov, P. Miller, S. Mitra, V. P. Mitrofanov, G. Mitselmakher, R. Mittleman, O. Miyakawa, S. Mohanty, V. Moody, G. Moreno, K. Mossavi, C. MowLowry, A. Moylan, D. Mudge, G. Mueller, S. Mukherjee, H. Muller-Ebhardt, J. Munch, P. Murray, E. Myers, J. Myers, T. Nash, G. Newton, A. Nishizawa, K. Numata, B. O’Reilly, R. O’Shaughnessy, D. J. Ottaway, H. Overmier, B. J. Owen, H.-J. Paik, Y. Pan, M. A. Papa, V. Parameshwaraiah, P. Patel, M. Pedraza, S. Penn, V. Pierro, I. M. Pinto, M. Pitkin, H. Pletsch, M. V. Plissi, F. Postiglione, R. Prix, V. Quetschke, F. Raab, D. Rabeling, H. Radkins, R. Rahkola, N. Rainer, M. Rakhmanov, M. Ramsuder, K. Rawlins, S. Ray-Majumder, V. Re, H. Rehbein, S. Reid, D. H. Reitze, L. Ribichini, R. Riesen, K. Riles, B. Rivera, N. A. Robertson, C. Robinson, E. L. Robinson, S. Roddy, A. Rodriguez, A. M. Rogan, J. Rollins, J. D. Romano, J. Romie, R. Route, S. Rowan, A. Rudiger, L. Ruet, P. Russell, K. Ryan, S. Sakata, M. Samidi, L. Sancho de la Jordana, V. Sandberg, V. Sannibale, S. Saraf, P. Sarin, B. S. Sathyaprakash, S. Sato, P. R. Saulson, R. Savage, P. Savov, S. Schediwy, R. Schilling, R. Schnabel, R. Schofield, B. F. Schutz, P. Schwinberg, S. M. Scott, A. C. Searle, B. Sears, F. Seifert, D. Sellers, A. S. Sengupta, P. Shawhan, D. H. Shoemaker, A. Sibley, J. A. Sidles, X. Siemens, D. Sigg, S. Sinha, A. M. Sintes, B. J. J. Slagmolen, J. Slutsky, J. R. Smith, M. R. Smith, K. Somiya, K. A. Strain, D. M. Strom, A. Stuver, T. Z. Summerscales, K.-X. Sun, M. Sung, P. J. Sutton, H. Takahashi, D. B. Tanner, M. Tarallo, R. Taylor, R. Taylor, J. Thacker, K. A. Thorne, K. S. Thorne, A. Thuring, K. V. Tokmakov, C. Torres, C. Torrie, G. Traylor, M. Trias, W. Tyler, D. Ugolini, C. Ungarelli, K. Urbanek, H. Vahlbruch, M. Vallisneri, C. Van Den Broeck, M. Varvella, S. Vass, A. Vecchio, J. Veitch, P. Veitch, A. Villar, C. Vorvick, S. P. Vyachanin, S. J. Waldman, L. Wallace, H. Ward, R. Ward, K. Watts, J. Weaver, D. Webber, A. Weber, A. Weidner, M. Weinert, A. Weinstein, R. Weiss, S. Wen, K. Wette, J. T. Whelan, D. M. Whitbeck, S. E. Whitcomb, B. F. Whiting, C. Wilkinson, P. A. Willems, L. Williams, B. Willke, I. Wilmut, W. Winkler, C. C. Wipf, S. Wise, A. G. Wiseman, G. Woan, D. Woods, R. Wooley, J. Worden, W. Wu, I. Yakushin, H. Yamamoto, Z. Yan, S. Yoshida, N. Yunes, M. Zanolin, J. Zhang, L. Zhang, PHYSICAL REVIEW D 77, 069904(E) (2008)
Published: 2007
Full Text: View/download PDF

44. Improving the timing precision for inspiral signals found by interferometric gravitational wave detectors

Author: F Acernese, P Amico, M Alshourbagy, F Antonucci, S Aoudia, P Astone, S Avino, D Babusci, G Ballardin, F Barone, L Barsotti, M Barsuglia, Th S Bauer, F Beauville, S Bigotta, S Birindelli, M A Bizouard, C Boccara, F Bondu, L Bosi, C Bradaschia, S Braccini, F J van den Brand, A Brillet, V Brisson, D Buskulic, E Calloni, E Campagna, F Carbognani, F Cavalier, R Cavalieri, G Cella, E Cesarini, E Chassande-Mottin, N Christensen, C Corda, A Corsi, F Cottone, A-C Clapson, F Cleva, J-P Coulon, E Cuoco, A Dari, V Dattilo, M Davier, M del Prete, R De Rosa, L Di Fiore, A Di Virgilio, B Dujardin, A Eleuteri, M Evans, I Ferrante, F Fidecaro, I Fiori, R Flaminio, J-D Fournier, S Frasca, F Frasconi, L Gammaitoni, F Garufi, E Genin, A Gennai, A Giazotto, G Giordano, L Giordano, R Gouaty, D Grosjean, G Guidi, S Hamdani, S Hebri, H Heitmann, P Hello, D Huet, S Karkar, S Kreckelbergh, P La Penna, M Laval, N Leroy, N Letendre, B Lopez, null Lorenzini, V Loriette, G Losurdo, J-M Mackowski, E Majorana, C N Man, M Mantovani, F Marchesoni, F Marion, J Marque, F Martelli, A Masserot, M Mazzoni, L Milano, F Menzinger, C Moins, J Moreau, N Morgado, B Mours, F Nocera, C Palomba, F Paoletti, S Pardi, A Pasqualetti, R Passaquieti, D Passuello, F Piergiovanni, L Pinard, R Poggiani, M Punturo, P Puppo, S van der Putten, K Qipiani, P Rapagnani, V Reita, A Remillieux, F Ricci, I Ricciardi, P Ruggi, G Russo, S Solimeno, A Spallicci, M Tarallo, M Tonelli, A Toncelli, E Tournefier, F Travasso, C Tremola, G Vajente, D Verkindt, F Vetrano, A Viceré, J-Y Vinet, H Vocca, M Yvert, Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux (ARTEMIS), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de l'Accélérateur Linéaire (LAL), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL), APC - Gravitation (APC-Gravitation), AstroParticule et Cosmologie (APC (UMR_7164)), Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Max-Planck-Gesellschaft-Max-Planck-Gesellschaft, Laboratoire des matériaux avancés (LMA), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Virgo, Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), VIRGO, Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux ( ARTEMIS ), Université Nice Sophia Antipolis ( UNS ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Observatoire de la Côte d'Azur, Université Côte d'Azur ( UCA ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de l'Accélérateur Linéaire ( LAL ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire d'Annecy de Physique des Particules ( LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules ), Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Université Savoie Mont Blanc ( USMB [Université de Savoie] [Université de Chambéry] ) -Centre National de la Recherche Scientifique ( CNRS ), ESPCI ParisTech, APC - Gravitation ( APC-Gravitation ), AstroParticule et Cosmologie ( APC - UMR 7164 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Observatoire de Paris-Université Paris Diderot - Paris 7 ( UPD7 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Observatoire de Paris-Université Paris Diderot - Paris 7 ( UPD7 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Max-Planck-Institut für Gravitationsphysik (Albert-Einstein-Institut), Max-Planck-Institut-Max-Planck-Institut, Laboratoire des matériaux avancés ( LMA ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Milano, Leopoldo, Calloni, Enrico, DE ROSA, Rosario, Garufi, Fabio, and Avino, Saverio
Subjects: Physics, Physics and Astronomy (miscellaneous), 010308 nuclear & particles physics, business.industry, Gravitational wave, Noise (signal processing), Physics::Instrumentation and Detectors, Detector, Binary number, Signal timing, 01 natural sciences, Signal, [ PHYS.GRQC ] Physics [physics]/General Relativity and Quantum Cosmology [gr-qc], Interferometry, Optics, 0103 physical sciences, [PHYS.GRQC]Physics [physics]/General Relativity and Quantum Cosmology [gr-qc], High Energy Physics::Experiment, 010306 general physics, business, Sensitivity (electronics)
Abstract: International audience; As they take data and improve their sensitivities, interferometric gravitational wave detectors will eventually detect signals emitted by inspiralling compact binary systems. Determining the sky position of the source will require that the signal be recorded in several detectors. The precision of the source direction determination will be driven by that of the time-of-flight measurements between detectors, and ultimately by the timing precision at the level of each detector. The latter is limited by the noise of the detector and the use of template banks, which introduce some mismatches between the parameters of the signal and the parameters of the template used to detect it. The standard way for signal timing is based on referring to the end time of the signal. In this paper we show that this is not an optimal choice and the timing precision can be improved referring to a time when the signal crosses some reference frequency, whose optimal value depends on the detector sensitivity.
Published: 2007
Full Text: View/download PDF

45. Analysis of noise lines in the Virgo C7 data

Author: F Acernese, P Amico, M Alshourbagy, F Antonucci, S Aoudia, P Astone, S Avino, D Babusci, G Ballardin, F Barone, L Barsotti, M Barsuglia, Th S Bauer, F Beauville, S Bigotta, S Birindelli, M A Bizouard, C Boccara, F Bondu, L Bosi, C Bradaschia, S Braccini, F J van den Brand, A Brillet, V Brisson, D Buskulic, E Calloni, E Campagna, F Carbognani, F Cavalier, R Cavalieri, G Cella, E Cesarini, E Chassande-Mottin, N Christensen, C Corda, A Corsi, F Cottone, A-C Clapson, F Cleva, J-P Coulon, E Cuoco, A Dari, V Dattilo, M Davier, M del Prete, R De Rosa, L Di Fiore, A Di Virgilio, B Dujardin, A Eleuteri, M Evans, I Ferrante, F Fidecaro, I Fiori, R Flaminio, J-D Fournier, S Frasca, F Frasconi, L Gammaitoni, F Garufi, E Genin, A Gennai, A Giazotto, G Giordano, L Giordano, R Gouaty, D Grosjean, G Guidi, S Hamdani, S Hebri, H Heitmann, P Hello, D Huet, S Karkar, S Kreckelbergh, P La Penna, M Laval, N Leroy, N Letendre, B Lopez, null Lorenzini, V Loriette, G Losurdo, J-M Mackowski, E Majorana, C N Man, M Mantovani, F Marchesoni, F Marion, J Marque, F Martelli, A Masserot, M Mazzoni, L Milano, F Menzinger, C Moins, J Moreau, N Morgado, B Mours, F Nocera, C Palomba, F Paoletti, S Pardi, A Pasqualetti, R Passaquieti, D Passuello, F Piergiovanni, L Pinard, R Poggiani, M Punturo, P Puppo, S van der Putten, K Qipiani, P Rapagnani, V Reita, A Remillieux, F Ricci, I Ricciardi, P Ruggi, G Russo, S Solimeno, A Spallicci, M Tarallo, M Tonelli, A Toncelli, E Tournefier, F Travasso, C Tremola, G Vajente, D Verkindt, F Vetrano, A Viceré, J-Y Vinet, H Vocca, M Yvert, Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux ( ARTEMIS ), Université Nice Sophia Antipolis ( UNS ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Observatoire de la Côte d'Azur, Université Côte d'Azur ( UCA ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de l'Accélérateur Linéaire ( LAL ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire d'Annecy de Physique des Particules ( LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules ), Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Université Savoie Mont Blanc ( USMB [Université de Savoie] [Université de Chambéry] ) -Centre National de la Recherche Scientifique ( CNRS ), ESPCI ParisTech, APC - Gravitation ( APC-Gravitation ), AstroParticule et Cosmologie ( APC - UMR 7164 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Observatoire de Paris-Université Paris Diderot - Paris 7 ( UPD7 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Observatoire de Paris-Université Paris Diderot - Paris 7 ( UPD7 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Max-Planck-Institut für Gravitationsphysik (Albert-Einstein-Institut), Max-Planck-Institut-Max-Planck-Institut, Laboratoire des matériaux avancés ( LMA ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Virgo, Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), VIRGO, Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux (ARTEMIS), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de l'Accélérateur Linéaire (LAL), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL), APC - Gravitation (APC-Gravitation), AstroParticule et Cosmologie (APC (UMR_7164)), Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Max-Planck-Gesellschaft-Max-Planck-Gesellschaft, Laboratoire des matériaux avancés (LMA), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), DE ROSA, Rosario, Garufi, Fabio, Milano, Leopoldo, Calloni, Enrico, Avino, Saverio, F., Acernese, Solimeno, Salvatore, Giordano, Lara, Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), and Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Physics, Physics and Astronomy (miscellaneous), 010308 nuclear & particles physics, business.industry, Astrophysics::Instrumentation and Methods for Astrophysics, 01 natural sciences, [ PHYS.GRQC ] Physics [physics]/General Relativity and Quantum Cosmology [gr-qc], Noise, Optics, Pulsar, Aliasing, Harmonics, 0103 physical sciences, Line (geometry), [PHYS.GRQC]Physics [physics]/General Relativity and Quantum Cosmology [gr-qc], Calibration, business, 010303 astronomy & astrophysics
Abstract: International audience; The paper presents a description of the work of detection and identification of frequency lines in the Virgo dark fringe data from run C7. A number of methods are highlighted by which noise frequency lines are detected by data analysis and measurements in the laboratory. In this paper we give a description of the list of noise line candidates provided by the pulsar search analysis, the investigation of 10 Hz (and harmonics) noise, violin modes, noise from the end station buildings' air conditioners, sidebands in calibration lines and aliasing in the 4 kHz reconstructed data.
Published: 2007
Full Text: View/download PDF

46. THU0363 A Structured Literature Review of the Burden of Illness and Unmet Needs in Patients with Rheumatoid Arthritis: A Current Perspective

Author: Peter C. Taylor, M. Tarallo, Adam W. Moore, Jose Alvir, and Radu Vasilescu
Subjects: medicine.medical_specialty, Physical disability, business.industry, Immunology, Alternative medicine, MEDLINE, Disease, PsycINFO, Mental health, General Biochemistry, Genetics and Molecular Biology, Quality of life (healthcare), Systematic review, Rheumatology, Family medicine, Physical therapy, Immunology and Allergy, Medicine, business
Abstract: Background Despite improvements in the attainable clinical and health outcomes for patients with rheumatoid arthritis (RA), the goals of remission or low disease activity still remain difficult to achieve in a substantial proportion of patients. While rheumatologists have focussed on attainment of these goals, for many patients, particularly those who do not achieve these targets, additional treatment goals are control over pain and fatigue, as well as maintaining physical function and quality of life (QoL). Objectives To examine patients9 treatment aspirations and to identify the unmet needs for patients with RA receiving ongoing treatment and the associated humanistic and economic burden. Methods Searches were performed using MEDLINE, Embase, PsycINFO and Econlit literature databases for articles published from 2004–2014 in the English language. Published literature was screened to identify articles reporting the burden of RA in patients receiving ongoing treatment. Core search terms included those related to the condition of study and treatment, and were combined with search terms related to humanistic and economic burden. Results A total of 3212 articles were identified. After removing conference abstracts and duplicates and screening titles and abstracts, 77 publications that reported on the humanistic (68 articles) and economic burden (9 articles) of RA were selected for full text review. Despite clinically meaningful improvements in pain with the introduction of effective treatment algorithms, patient scores remained below the acceptable threshold in those receiving biologic therapy (1), whereas patients with RA receiving ongoing treatment with conventional disease-modifying antirheumatic drugs continued to experience moderate pain (2). Other health outcomes such as physical disability persisted above the threshold that patients would consider acceptable (3, 4) and mental health needs were also insufficiently met in a large proportion of patients with RA receiving ongoing treatment (5). In Europe, the health burden of RA was associated with an economic burden of € 45.3 billion, affecting patients, their families and society (6). Conclusions Despite ongoing advances in the treatment of RA, many patients receiving currently available therapies continue to experience substantial disability and suboptimal QoL. RA is a multifaceted disease that can impact on individual patients in a variety of ways, some objectively evident and others known only to the patient themselves. Although a broad range of available pharmaco-therapeutic and management options are currently available, novel treatments and approaches are needed to address the associated unmet needs. References Fleischmann R. Open Access Rheumatology Research and Reviews. 2009;1:95–106. Gronning K, Rodevand E, Steinsbekk A. Clin Rheumatol. 2010;29:1317–1322. Westhovens R, Cole JC, Li T, et al. Rheumatology (Oxford). 2006;45:1238–1246. Wells GA, Tugwell P, Kraag GR, Baker PRA, Groh J, Redelmeier DA. The Journal of Rheumatology. 1993;20:557–560. Strand V, Singh JA. Drugs. 2010;70:121–145. Lundkvist J, Kastang F, Kobelt G. Eur J Health Econ. 2008;Suppl 2:S49–60. Acknowledgements Medical writing support was provided by Neel Misra of Engage Scientific Solutions and was funded by Pfizer Inc. Disclosure of Interest P. Taylor Consultant for: Pfizer, A. Moore: None declared, R. Vasilescu Shareholder of: Pfizer, Employee of: Pfizer, J. Alvir Shareholder of: Pfizer, Employee of: Pfizer, M. Tarallo Shareholder of: Pfizer, Employee of: Pfizer
Published: 2015
Full Text: View/download PDF

47. Coincidence analysis between periodic source candidates in C6 and C7 Virgo data

Author: F Acernese, P Amico, M Alshourbagy, F Antonucci, S Aoudia, P Astone, S Avino, D Babusci, G Ballardin, F Barone, L Barsotti, M Barsuglia, Th S Bauer, F Beauville, S Bigotta, S Birindelli, M A Bizouard, C Boccara, F Bondu, L Bosi, C Bradaschia, S Braccini, F J van den Brand, A Brillet, V Brisson, D Buskulic, E Calloni, E Campagna, F Carbognani, F Cavalier, R Cavalieri, G Cella, E Cesarini, E Chassande-Mottin, N Christensen, C Corda, A Corsi, F Cottone, A-C Clapson, F Cleva, J-P Coulon, E Cuoco, A Dari, V Dattilo, M Davier, M del Prete, R De Rosa, L Di Fiore, A Di Virgilio, B Dujardin, A Eleuteri, M Evans, I Ferrante, F Fidecaro, I Fiori, R Flaminio, J-D Fournier, S Frasca, F Frasconi, L Gammaitoni, F Garufi, E Genin, A Gennai, A Giazotto, G Giordano, L Giordano, R Gouaty, D Grosjean, G Guidi, S Hamdani, S Hebri, H Heitmann, P Hello, D Huet, S Karkar, S Kreckelbergh, P La Penna, M Laval, N Leroy, N Letendre, B Lopez, null Lorenzini, V Loriette, G Losurdo, J-M Mackowski, E Majorana, C N Man, M Mantovani, F Marchesoni, F Marion, J Marque, F Martelli, A Masserot, M Mazzoni, L Milano, F Menzinger, C Moins, J Moreau, N Morgado, B Mours, F Nocera, C Palomba, F Paoletti, S Pardi, A Pasqualetti, R Passaquieti, D Passuello, F Piergiovanni, L Pinard, R Poggiani, M Punturo, P Puppo, S van der Putten, K Qipiani, P Rapagnani, V Reita, A Remillieux, F Ricci, I Ricciardi, P Ruggi, G Russo, S Solimeno, A Spallicci, M Tarallo, M Tonelli, A Toncelli, E Tournefier, F Travasso, C Tremola, G Vajente, D Verkindt, F Vetrano, A Viceré, J-Y Vinet, H Vocca, M Yvert, Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux (ARTEMIS), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de l'Accélérateur Linéaire (LAL), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Annecy de Physique des Particules (LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), ESPCI ParisTech, APC - Gravitation (APC-Gravitation), AstroParticule et Cosmologie (APC (UMR_7164)), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Observatoire de Paris, PSL Research University (PSL)-PSL Research University (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Max-Planck-Gesellschaft-Max-Planck-Gesellschaft, Laboratoire des matériaux avancés (LMA), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Virgo, Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), VIRGO, COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut national des sciences de l'Univers (INSU - CNRS)-Observatoire de la Côte d'Azur, Université Côte d'Azur (UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Laboratoire d'Annecy de Physique des Particules (LAPP), Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL), Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11)-Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Observatoire de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS)-Max-Planck-Institut für Gravitationsphysik ( Albert-Einstein-Institut ) (AEI), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Astrophysique Relativiste Théories Expériences Métrologie Instrumentation Signaux ( ARTEMIS ), Université Nice Sophia Antipolis ( UNS ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Institut national des sciences de l'Univers ( INSU - CNRS ) -Observatoire de la Côte d'Azur, Université Côte d'Azur ( UCA ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire de l'Accélérateur Linéaire ( LAL ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire d'Annecy de Physique des Particules ( LAPP/Laboratoire d'Annecy-le-Vieux de Physique des Particules ), Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Université Savoie Mont Blanc ( USMB [Université de Savoie] [Université de Chambéry] ) -Centre National de la Recherche Scientifique ( CNRS ), APC - Gravitation ( APC-Gravitation ), AstroParticule et Cosmologie ( APC - UMR 7164 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Observatoire de Paris-Université Paris Diderot - Paris 7 ( UPD7 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Observatoire de Paris-Université Paris Diderot - Paris 7 ( UPD7 ) -Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Max-Planck-Institut für Gravitationsphysik (Albert-Einstein-Institut), Max-Planck-Institut-Max-Planck-Institut, Laboratoire des matériaux avancés ( LMA ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de Physique Nucléaire et de Physique des Particules du CNRS ( IN2P3 ) -Centre National de la Recherche Scientifique ( CNRS ), DE ROSA, Rosario, Solimeno, Salvatore, Garufi, Fabio, Milano, Leopoldo, Avino, Saverio, F., Acernese, Calloni, Enrico, L., Di Fiore, and Giordano, Lara
Subjects: Physics, Hierarchical search, Physics and Astronomy (miscellaneous), 010308 nuclear & particles physics, Gravitational wave, Pipeline (computing), Astrophysics, Parameter space, 01 natural sciences, Coincidence, [ PHYS.GRQC ] Physics [physics]/General Relativity and Quantum Cosmology [gr-qc], HIERARCHICAL SEARCH, Neutron star, 0103 physical sciences, Range (statistics), [PHYS.GRQC]Physics [physics]/General Relativity and Quantum Cosmology [gr-qc], False alarm, 010306 general physics
Abstract: International audience; In this paper, we describe the analysis performed in the data of C6 and C7 commissioning runs of Virgo for the search of periodic sources of gravitational waves. The analysis is all-sky, covers the frequency range between 50 Hz and 1050 Hz and neutron star spin-down rate below 1.58 × 10-8 Hz s-1. Coincidences in the source parameter space between candidates found in the two data sets are required to reduce the false alarm probability. The procedure used to estimate the detection efficiency of the analysis pipeline, through the injection of simulated signals in the data, is also described.
Published: 2006
Full Text: View/download PDF

48. Boron requirement in soybean cultivars

Author: Hipólito Assunção Antonio Mascarenhas, M. Tarallo, A. M. C. Furlani, R. T. Tanaka, and M. F. Verdial
Subjects: Nutrient solution, Chemistry, solução nutritiva, fungi, Randomized block design, micronutriente, food and beverages, Soil Science, nutrient solution, Micronutrient, lcsh:S1-972, plant selection, seleção de cultivares, Horticulture, Nutrient, Agronomy, Toxicity, micronutrient, Glycine max (L.) Merrill, Dry matter, Cultivar, Plant breeding, lcsh:Agriculture (General), Agronomy and Crop Science
Abstract: O conhecimento quanto à exigência a boro de genótipos da soja pode ser relevante para: recomendações de corretivos e fertilizantes, recomendação de cultivares e programas de melhoramento. O objetivo deste trabalho foi estudar a resposta de cultivares de soja à adição de doses de boro em solução nutritiva. O experimento foi realizado em casa de vegetação do Instituto Agronômico de Campinas - IAC, Campinas (SP). Foram estudados quatro cultivares de soja (IAC-1, IAC-8, IAC-15 e IAC-17) e cinco doses de boro (0,0; 0,05; 0,20; 0,80 e 2,00 mg L-1 de B), utilizando-se delineamento em blocos ao acaso, em esquema fatorial com cinco repetições. As plantas foram avaliadas quanto aos sintomas de deficiência à toxidez, produção de matéria seca, altura das plantas, teores críticos de B nas folhas, B absorvido pela planta e teores de P, K, Ca e Mg. As plantas foram colhidas no início do florescimento para determinação da massa da matéria seca e teores de nutrientes. Os teores limites de B nas folhas para a deficiência variaram de 25 a 30 mg kg-1, mostrando diferenças entre os cultivares nesta susceptibilidade. O sintoma inicial de toxidez foi observado a partir da dose de 0,8 mg L-1 de B na solução, cujo teor correspondente nas folhas foi de 83 mg kg-1 de B (média dos cultivares), enquanto o acúmulo máximo de matéria seca total ocorreu para concentrações na solução estimadas entre 0,1 e 0,2 mg L-1. A severidade dos sintomas visuais variou entre cultivares dentro do mesmo tratamento, indicando diferentes tolerâncias ao excesso do nutriente. Assim, quanto aos sintomas de deficiência e de toxidez, o cv. IAC-1 foi o mais susceptível à deficiência e à toxidez de B, e o cv. IAC-17 foi, aparentemente, o mais tolerante ao excesso de B. Os cvs. IAC-8 e o IAC-15 acumularam as maiores quantidades de B, mesmo nos tratamentos com baixa concentração de B na solução. Os teores de P, K, Ca e Mg nas folhas não variaram significativamente entre os tratamentos que receberam boro (0,05 a 2,0 mg L-1), com exceção das plantas com deficiência severa. The evaluation and classification of soybean cultivars, based on their tolerance to deficient or excessive boron levels, may be relevant when recommending fertilizers and amendments, and for plant breeding programs. This research aimed to study the response of four soybean cultivars to doses of B added to the nutrient solutions. The experiment was carried out under greenhouse conditions, at the experimental station of Instituto Agronômico, Campinas, São Paulo, Brazil in 1998. The soybean cultivars IAC-1, IAC-8, IAC-15 e IAC-17 were grown in five B concentrations in a nutrient solution (0.0; 0.05; 0.2; 0.8 and 2.0 mg L-1 of B), in order to get a wide range of plant response, from deficiency to toxicity. The experiment was arranged in a randomized complete block design, in a factorial with five replications. The plants were evaluated for visual symptoms of deficiency and toxicity, top and root dry matter production, plant height, leaf B critical concentrations for deficiency or toxicity, B contents in plant parts (top/root ratios), and leaf P, K, Ca and Mg concentrations. Plants were harvested at early flowering and separated in leaves, stems and roots for dry matter and nutrient determinations. The critical concentration in the leaves for deficiency symptoms varied from 25 to 30 mg kg-1, and different susceptibilities among cultivars for B deficiency were observed. Visual symptoms of toxicity started at levels of 0.8 mg L-1, which were related to an average leaf B concentration of 83 mg kg-1. Maximum total dry matter yields were obtained for concentrations in the nutrient solution estimated between 0.1 and 0.2 mg L-1. The severity of visual symptoms varied among cultivars within the same treatment, indicating different tolerances to B excess. In relation to the visual symptoms, cv. IAC-1 was the most susceptible to B deficiency and B toxicity; cv. IAC-17 was, apparently, the most tolerant to B toxicity. Cultivars IAC-8 and IAC-15 were more efficient in the uptake and accumulation of B, even under low B concentrations in solution. The cultivars presented similar B transport ability from roots to tops evaluated by the top/root ratios of B content, except for the cv. IAC-17. Leaf nutrient (P, K, Ca and Mg) concentrations did not vary significantly with the increasing B concentrations in the solution (0.05 to 2.0 mg L-1), except for the severely deficient plants.
Published: 2001

49. Spinalioma destruente su ulcera da decubito

Author: Alfano, Carmine and B. Carlesimo, M. Tarallo
Published: 2000

50. Burden of Dose Escalation with Biologics in Rheumatoid Arthritis: A Review of Frequency and Costs

Author: R. Mays, Robert J. Moots, C. Li, Jennifer Stephens, and M. Tarallo
Subjects: Oncology, medicine.medical_specialty, business.industry, Health Policy, Internal medicine, Rheumatoid arthritis, Public Health, Environmental and Occupational Health, medicine, Dose escalation, business, medicine.disease
Published: 2013
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

160 results on '"M., Tarallo"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources